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Chapter 1
Increased healthcare utilisation and shortage of caregivers
The prevalence of chronic conditions is on the rise worldwide, because of 
increased longevity, urbanisation and the spread of unhealthy lifestyles. (1) 
Already the demand for care exceeds the supply, and shortages are expected to 
increase due to a continuing rise in healthcare utilisation. (2, 3) The World Health 
Organization (WHO) estimates that 400 million people worldwide lack access 
to the most essential health services at the moment. (2) Furthermore, the WHO 
predicts that by 2030 the shortage of health workers will increase to 18 million 
people. (3) This shortage in care mainly affects the vulnerable and marginalised 
populations, thereby increasing inequality in care. (4) Moreover, even in western 
countries this increasing demand on care, combined with the increasing shortage 
of caregivers, endangers the affordability of their, often already overextended, 
healthcare systems. (5)
Changes in the approach to health
Whereas in the past healthcare concentrated on the cure of diseases, nowadays, 
improved therapeutic options enable an increasing number of people to live 
with chronic diseases that require lifelong care. This change from cure to care 
requires a shift in the way healthcare is organised. (1) Because the management 
of chronic diseases involves the handling of long-term health issues, it provides 
the opportunity to personalise care and allows for more patient involvement 
in the management of their disease. This has led to a shift from a paternalistic 
model of healthcare, to a more equal model, centred on patient values. In this new 
model shared decision-making by caregiver and caretaker is paramount. (1) This 
new interplay between patient and health professional led to a new vision of the 
concept of health. In 1948 the WHO stated “health is a state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity”. 
While this definition was ground-breaking at the time, because it included the 
physical, mental and social domains, the criticism on it has intensified over the 
years. Because this WHO definition requires a “complete” state of well-being, it 
is argued that: “it would leave most of us unhealthy all the time”. (6) Therefore, in 
2011 Hubert et al. coined the term positive health, defined as “the ability to adapt 
and to self-manage, in the face of social, physical and emotional challenges”. (7) 
This definition of positive health is more centred on the patients’ perspective and 
assumes active involvement in personal wellbeing.
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Patient participation and self-management
Many politicians and academics in Europe believe that this changing relationship 
between caregiver and caretaker along with the increased patient participation 
will lighten the current burden on the healthcare system and its workers. (8) 
The importance of patient participation is also recognised by the WHO, which 
promotes self-management as an innovative approach to improve health coverage 
for all. According to the WHO self-management is not only associated with 
increased coverage and access, but also with reduced health disparities and 
increased equity, reduced cost, more efficient use of health-care resources and 
services, and an increased quality of services. (4) In order to further stimulate 
patient participation and self-management many innovative strategies have 
already been implemented. (9-11)
Healthcare of the future
In the future, according to the “Dutch Hospital Association” (NVZ), an increasing 
amount of care will need to be delivered with an equal capacity of people and 
resources in order to uphold the affordability of care. To achieve this, the patient 
has to become a partner in care and the healthcare system has to optimise the use 
of innovative techniques and medication. (12) That patients could be a valuable 
partner in health is illustrated by the International Center for Self-Care Research 
(ICSCR): “Of 8,760 hours in a year, only about 10 hours or 0.001% are spent 
with healthcare professionals. All other health maintenance, monitoring and 
management activities are done by individuals and their families as self-care 
activities”. (13) Increasing the responsibility patients feel for their own health, will 
improve their self-management behaviour. (12, 14) Innovations in diagnostics, 
devices, digital services and treatment options are already transforming the way 
in which people interact with the health sector. (4) Some examples of successfully 
implemented innovations are, for instance: the glucose meter, which enables 
patients to measure their glucose from home, and the Holter monitor, nowadays 
sent to the patient’s home together with a do-it-yourself instruction. (15, 16) 
However, not every innovation is implemented successfully. For example, the 
adequate use of eHealth applications remains difficult. These applications are 
often deployed to facilitate self-management, enhancing participation in care. 
(17) However, even though a broad variety of these kind of eHealth applications 
is available, the number of chronic patients performing self-management remains 
low. (18) It is expected that with further development of the applications and 
1
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increased awareness of eHealth among patients and health professionals, the use 
of these applications will increase over time. (19) Also the implementation of new 
medication, often grouped together as “expensive medication” because of their 
high development costs, remains challenging (20). These drugs are often very 
effective and have changed the disease course of many illnesses. (21) Therefore, 
their use has increased tremendously over the last decades. The downside of 
this is, that prescription of “expensive medication” is slowly displacing other 
care. Between 2012 and 2016 there was a 19 percent increase in the expenditure 
on “expensive medication”, amounting to 8.4 percent of the Dutch healthcare 
budget. (22) The hope is that the increased use of unpatented medication will 
help to bring down the cost for expensive medication, thereby increasing the 
affordability of care. (23-28)
Cost and need for innovations in rheumatic care
The care for rheumatic diseases is one of the medical fields where care for chronic 
diseases and promising innovations collide. Rheumatic diseases are chronic, 
systemic auto-inflammatory diseases which mainly affect the joints. About 5 
percent of the general population suffers from a chronic inflammatory rheumatic 
disease, resulting in both social and economic impact. (29) For example, 
rheumatoid arthritis (RA) comes with a significant financial burden through 
both direct medical costs and indirect costs, because of its chronic character, the 
need for livelong medical treatment and its tendency to lead to disability. (30) 
The direct medical costs account for about 20% of the average total costs for a 
patient with RA. (30) The direct costs are highly skewed (to the right) because 
a small subgroup of the RA population accounts for a large proportion of the 
costs, through the use of “expensive medication”. (27) It is expected that the use 
of biosimilars as an alternative to the more expensive bio-originators will lead to 
a significant reduction of medication cost. (23-28) Biosimilars are biotherapeutic 
products (biologics) that are similar in terms of quality, safety and efficacy to 
an already licensed reference biotherapeutic product (bio-originator). (31) That 
price competition initiated through the introduction of biosimilars leads to lower 
prices is shown by the 89% discount offered on the Adalimumab bio-originator 
in the Netherlands in the first year after market approval of the biosimilar. (32) 
However, the effect of lower prices on the utilisation of biologics and thereby the 
effect on health budgets remains unclear. (24) The change in healthcare cost may 
be positive or negative depending on the magnitude of the price reduction, the 
556700-L-bw-Muskens
Processed on: 29-4-2021 PDF page: 11
11 
Introduction
prescriber response to lower prices in terms of volume, and the cost-effectiveness 
of expanded access to biologics. (24) The method of transitioning patients to the 
biosimilar is also relevant when it comes to the cost-effectiveness of biosimilars. 
It is unclear whether a transition based on shared decision-making or a mandatory 
transition yields better results. (33)
The indirect costs amount to around 80% of the average costs of a RA 
patient. (30) Main contributors for indirect costs are incapacity for work and 
costs of sick leave, but the loss of ability to perform unpaid work (when valued 
in monetary terms) also plays an important role. Research has shown that costs 
are correlated with disease activity, and disability. (30) Therefore, improvement 
of disease control and reduction of disability is expected to lower the cost of 
rheumatic diseases. Literature already indicates that patient empowerment and 
patient participation leads to better satisfaction, concordance with treatment 
and improved health outcomes, such as lower functional disability and less 
pain and fatigue. (34-38) Moreover, patient engagement is recognised as having 
a major role in improving quality and safety of health care interventions. (39) 
Therefore, innovations aimed at empowering patients and improving patient 
participation in rheumatic care seem a logical step to improve healthcare and 
lower healthcare costs.
The rheumatology department of Bernhoven as case-study
The Rheumatology department of Bernhoven, a general hospital in The 
Netherlands, has tried to incorporate and promote a shared decision way of 
working in daily clinical practice, in line with the NVZ vision for care and the 
vision of Bernhoven for shared decision making called “Samen beslissen”. (12, 
40) Therefore, the eHealth platform Reumanet was implemented in Bernhoven 
in 2017, replacing the online rheumatology register Mijnreumacentrum that had 
been active since 2014. Reumanet aims to improve healthcare for rheumatic 
patients, by offering insight in the individual disease course and by increasing 
the ability to self-manage their disease. In Reumanet patients can monitor their 
disease activity by completing questionnaires about, for instance: pain, fatigue, 
physical activity level, quality of life, and they have access to their medication 
history. The web-based system also offers the patient information in the form 
of an online library, with written information and video material regarding 
RA. Next to being in agreement with the EULAR principle concerning shared 
decision-making, (41) the eHealth platform also offers an excellent format 
1
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to monitor the medication flow in RA patients over time and evaluate the 
effectiveness of given treatments in a common practice setting. During this 
period Bernhoven introduced a biosimilar for Etanercept. As part of regular care 
all patients starting Etanercept treatment from June 2016 onwards were started 
on the biosimilar. Next to that, all patients being treated with the Etanercept 
bio-originator were offered to transition to the biosimilar based on a shared 
decision-making approach. This transition offers the opportunity to study the 
influence of biosimilars on care in daily clinical practice.
Evaluation of interventions in daily clinical practice
Many researchers view the randomised controlled trial (RCT) as the gold standard 
for effectiveness studies. (42) However, due to their controlled setting, results, 
often with high internal validity, do not allow for widespread extrapolation. 
(43) RCTs give an estimate of how an intervention performs under ideal and 
controlled circumstances. Therefore, they are suitable for the investigation of 
efficacy of a treatment. (44) Effectiveness, however, refers to the performance of 
an intervention under ‘real-world’ conditions. Observational or pragmatic studies, 
based on real world-data often offer a higher external validity, because they take 
place in the target population. (43, 44) The real-world data are collected during 
routine healthcare and represent the real-world effectiveness of interventions. This 
data is essential for policy makers, who are interested in the cost-effectiveness 
of certain interventions. They need to be aware not only of the efficacy of a 
treatment, but also of the effectiveness in daily clinical practice. This thesis 
reports on the real-world data collected on interventions in rheumatic care.
The aim of the thesis
The aim of this thesis was to investigate the introduction of two innovations 
on care delivered in daily clinical practice at the rheumatology department of 
Bernhoven. Firstly, the introduction of the eHealth platform Reumanet and a self-
management outpatient clinic was investigated. Secondly, the introduction of a 
biosimilar in the treatment of inflammatory rheumatic diseases was analysed. 
Both the cost-savings aspect and the effects of shared decision-making on the 
implementation of the biosimilar were studied. This led to the following content 
of this thesis:
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Chapter 2 evaluates the use of Reumanet and the self-management outpatient 
clinic in Bernhoven. The effect of implementation of Reumanet on trends in 
quarterly healthcare utilisation and disease activity are analysed.
Chapter 3 reports on different methods used for the transitioning to biosimilars 
in the treatment of inflammatory auto-immune diseases in the Netherlands. 
The different methods are compared, regarding observed acceptance and 
retention rates.
Chapter 4 describes the transition from Etanercept bio-originator to an 
Etanercept biosimilar in the treatment of inflammatory rheumatic diseases in 
Bernhoven. The effect of shared decision-making on the acceptance rate and 
one-year retention rate of the biosimilar is studied.
Chapter 5 measures the effect of introducing biosimilars on medication cost in 
a population of patients with rheumatoid arthritis. Trends in quarterly total and 
average medication cost are studied.
Chapter 6 discusses the main findings of this thesis, considers the methods and 
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CHAPTER 2
Telemedicine in the management of rheumatoid arthritis: 
maintaining disease control with less healthcare 
utilization
Wieland D Müskens, Sanne A A Rongen-van Dartel, Carine Vogel, Anita 
Huis, Eddy M M Adang, Piet L C M van Riel
Rheumatology Advances in Practice, 10.1093/rap/rkaa079
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We aimed to evaluate the use of an eHealth platform and a self-management 
outpatient clinic in patients with rheumatoid arthritis (RA) in a real-world setting. 
The effect on healthcare utilization and disease activity were studied.
Methods
Using hospital data of patients with RA between 2014 and 2019, the use of an 
eHealth platform and participation in a self-management outpatient clinic were 
studied. An interrupted time series analysis compared the period before and after 
the introduction of the eHealth platform. The change in trend (relative to the 
pre-interruption trend) for the number of outpatient clinic visits and the disease 
activity score 28-joints (DAS28) was determined for several scenarios.
Results
After the platform’s implementation in April 2017, the percentage of patients 
using it was stable around 37%. On average, the users of the platform were 
younger, more highly educated and had better health outcomes than the total 
RA population. After the implementation of the platform, the mean number 
of quarterly outpatient clinic visits per patient decreased by 0.027 per quarter 
(CI = [-0.045;-0.08], p-value = 0.007). This was accompanied by a significant 
decrease in DAS28 of 0.056 per quarter (CI = [-0.086;-0025], p-value = 0.001). 
On average this resulted in 0.955 less visits per patient per year and a 0.503 
reduction in the DAS28
Conclusions
The implementation of remote patient monitoring has a positive effect on 
healthcare utilization, while maintaining low disease activity. This should 
encourage the use of this type telemedicine in the management of RA, especially, 
when many routine outpatient clinic visits are cancelled due to COVID-19.
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Introduction
The World Health Organization estimates that by 2030 there will be a shortage 
of 18 million health workers, due to further increase in healthcare utilization.(1) 
In Western countries the increasing prevalence of chronic diseases is a growing 
burden to an already overextended healthcare system.(2) For rheumatic services, 
the demand is exceeding supply, as reflected by long waiting lists in many 
countries.(3) The expectation is that this demand will continue to increase over 
the coming years.(4) Simultaneously, the workforce is declining due to an aging 
population, while developments in labor productivity in healthcare are lagging.
(5, 6) Therefore, structural changes are needed to deliver an increasing amount of 
care with the same capacity of people and resources.(7) According to the Dutch 
Health Authority, a more rapid introduction of digitalization in healthcare is 
needed..(8) Digitalization can help optimize healthcare by improving the lagging 
productivity(6) Both the potential and importance of digitalization have become 
even clearer in recent months, as it was impossible to deliver care as usual due 
to the arrival of the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2).(9)
For instance telemedicine, i.e. delivery of healthcare services through the 
use of information and communication technologies in a situation where the 
actors are in different locations: remote monitoring,(10) can be used to partly 
replace outpatient visits and other laborintensive care.(7, 8) The management of 
rheumatoid arthritis (RA) lends itself for the use of remote monitoring. RA is a 
chronic disease that often requires lifelong hospital visits. Because of the routine 
character (every 3-6 months) of these hospital visits, and the variable disease 
course of RA, oftentimes patients are doing well at the time of consultation and 
little action is needed. (11) At the same time, routine outpatient visits are unable 
to support patients if they experience a flare of their disease in between visits.
(12) By supporting self-management and giving education about the disease in 
general, patients will gain more insight in the individual course of their disease. 
This will help patients manage their disease better, which in turn will improve 
their health outcome.(13)
The first studies evaluating remote monitoring for the treatment of rheumatic 
diseases are promising, with high patient satisfaction and equal or higher 
effectiveness compared to the face-to-face approach.(14, 15) The use of Patient 
Reported Outcome Measures (PROMs) to assess disease activity and patient-
2
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initiated visits makes it possible to achieve similar disease control with fewer out-
patient clinic visits.(16, 17) However, research settings the patients participating 
in these remote monitoring programs are often a selective group. This group 
consists of patients that are younger or less sick, (15) often with a higher level of 
education. (18) This selection reflects that there is still a large group which feels 
reluctant to participate in remote monitoring programs and telemedicine.(19)
However, telemedicine is not merely a change in organization and coordination 
of care. It is especially a different way of thinking about care as a system, and 
the position of patients in it.(20) A prerequisite for telemedicine to be successful, 
is that patients become a partner in care.(7) Therefore, to support patients in 
their self-management behavior and improve patient engagement, the eHealth 
platform Reumanet Bernhoven was introduced in April 2017.(21) Reumanet is 
an eHealth platform which helps patients and health professionals manage the 
rheumatic disease. The aim of this platform is to increase the number of patients 
that feels adequately equipped to perform self-management and improve patient 
engagement on population level.
At the same time, research shows that successful disease-monitoring by the 
patient helps replace lifelong physician-initiated visits with patient-initiated 
visits.(15) This will reduce the number of routine visits of patients with stable 
disease, creating more time to review patients with an active disease in a timely 
manner. In order to teach patients, the competencies required for successful 
self-managements, the “self-management outpatient clinic” (SMOC) was started 
in March 2018 in Bernhoven. In the SMOC, patients are coached by a trained 
nurse specialist to use their own abilities to self-monitor their disease (facilitated 
through the eHealth platform). This aims to reduce the number of unnecessary 
hospital visits, while maintaining disease control.
This study has three aims:
- To evaluate the use of an eHealth platform and the different levels of 
participation.
- To study the influence of introducing an eHealth platform promoting self- 
management on disease activity and the number of hospital visits in the RA 
population.
- To study the impact of remote-monitoring on healthcare utilization and the 
disease activity of patients with RA.
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Methods
Design
This observational study evaluates the use of an eHealth platform and different 
levels of participation in the Department of rheumatology at Bernhoven using 
a real-world design setting. Next to that, it studies the effects of implementing 
an eHealth platform with regard to disease activity and healthcare utilization 
using an interrupted time series design between July 2014 and October 2019. 
The study also analyses the patients participating in the SMOC and their disease 
activity and healthcare utilization. Data on all patients with a clinical diagnosis 
of RA according to the 2010 ACR criteria were collected from the Reumanet 
registry and included in the analysis. (22) All patients had provided written 
informed consent for the use of their data for scientific purposes at an earlier time 
point. All procedures were performed in accordance with the ethical standards 
of the institutional and national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards. According 
to the medical ethical review committee of the region Arnhem- Nijmegen, this 
study does not require ethical approval, since only data used for daily clinical 
practice were collected. File number 2020-6729.
Reumanet Bernhoven
In April 2017 the eHealth platform Reumanet Bernhoven (Philips VitalHealth 
software) was launched.(21) The platform includes data on all patients diagnosed 
with RA under treatment at the rheumatology department Bernhoven and is 
automatically available for the patient and the rheumatologist. With permission 
of the patient, other health professionals can also gain access, e.g. the nurse, 
general practitioners or physiotherapist. The platform provides the patient with 
disease specific information in the form of a library, contains eHealth modules, 
and gives insight in personal medical data, like medication history and laboratory 
values. Patients can also monitor their disease activity by using PROMs. Next 
to that, Reumanet includes graphical overviews of disease activity and PROMs, 
lifestyle advices and a chat function is available to send messages between patient 
and health professional. To improve uptake of Reumanet, special attention was 
given to make the process as inclusive as possible.
2
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For example, educational classes how to log in and use Reumanet were offered 
to support those who lacked skills and reminders to fill out questionnaires were 
sent to patients at patient specific time points.
Self-management outpatient clinic
The SMOC was initiated in March 2018. The aim of this outpatient clinic was 
to provide patients who are in remission or have low disease activity with 
the opportunity to self-manage their disease and thereby reduce the number 
of consultations at the department of rheumatology. Patients with a clinical 
diagnosis of RA, either in stable remission or with low disease activity, who were 
motivated to take part in the self-management program and able to use Reumanet 
were invited to participate in the SMOC. After giving informed consent, the 
patient received information by a trained nurse specialist about the aim of the 
SMOC, how to use Reumanet, what to expect from the health professionals 
and how to contact the outpatient clinic in case they had questions. Patients 
participating in the SMOC were required to have one consultation with the 
rheumatologist per year and were asked to fill in the Rheumatoid Arthritis Impact 
of Disease (RAID)(23) to track their disease activity. Patients were obliged to 
undergo laboratory monitoring according to the guidelines of the drugs they 
were using. The samples could be taken at a location of patients’ choice and were 
analyzed at the laboratory of Bernhoven. The results of these test were reviewed 
by the healthcare professionals before sending a medication prescription for the 
consecutive period. Patients were able to contact a nurse specialist if they felt the 
need to, for example because of a self-monitored flare or an adverse event and 
get a consultation within a few days if the patient or nurse practitioner deemed 
this desirable.
Measures
Baseline characteristics: age, gender, educational status, work status, smoking 
status, alcohol use, disease duration, rheumatoid factor (RF) status, anti–
citrullinated protein (anti-ccp) status, BMI, medication use. As a measure of 
healthcare utilization the number of RA related outpatient clinic visits was 
used. The DAS28 was used by the rheumatologist as a measure for disease 
activity (score between 0 and 10; higher score indicated higher disease activity).
(24) The following PROMS were filled out: for functional capacity the Health 
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Assessment Questionnaire (HAQ)(25) was used (score between 0 and 3; higher 
score indicated worse function and greater disability); The 36-Item Short Form 
Health Survey (SF-36)(26) was used to measure health related quality of life 
(score between 0 and 100; higher score indicated a better health related quality of 
life); To assess the impact of RA from a patient perspective the RAID was scored 
(score between 0 and 10; higher scores indicated a worse impact of disease). The 
following measurements and questionnaires could be entered by the patient: 
educational status, working status, smoking status, alcohol use, HAQ, SF36, 
RAID and visual analog scales for pain and tiredness.
Evaluation of self-management through use of the eHealth platform
To evaluate the utilization of the eHealth platform we categorized the RA 
population based on the level of utilization. First, we divided the population into 
two groups: patients that had an email address and therefore had the possibility 
to login into Reumanet (potential users), and patients without the possibility 
to login (non-users). Secondly, we identified the subgroup of patients who had 
actually logged in (active users). Because Reumanet offers the possibility to fill 
out yearly questionnaires, a one-year cut-off was used to identify active users. 
Thirdly, we identified those patients who regularly performed PROMs as part 
of follow-up within the SMOC.
Interrupted time series analyses analyzing the introduction of an 
eHealth platform
To study the effect of introducing Reumanet on healthcare utilization and disease 
activity a single center interrupted time series analysis was performed in the 
total population and in the subgroup of patients that eventually participated in 
the SMOC. The interruption in the time series (quarterly intervals) was placed 
at April 2017 i.e. the introduction of the platform. The interrupted time series 
design attempts to assess whether the Reumanet intervention had a significant 
effect on healthcare utilization and DAS28 compared to the underlying trend. 
The pre-intervention trend serves as the control. (27)Autocorrelation in the error 
distribution is tested by the Cumby–Huizinga general test for autocorrelation. 
Depending on the outcome of this test, one or more lags are added to the model. 
Statistical analyses were done in STATA 15.1
2
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Participation in Reumanet and the self-management outpatient clinic
Since the initiation of the eHealth platform and the SMOC, the utilization of these 
programs increased gradually over time (Figure 1). However, most of the uptake 
of Reumanet occurred in the quarter immediately following its introduction, 
and it was difficult to increase this number over time. By November 2019, 1145 
patients with RA were treated at the rheumatology department of Bernhoven and 
therefore included in Reumanet. By then, 818 (71 percent of the RA population) 
had uploaded their email address and were able to login to Reumanet. Of those, 
434 patients (38 percent of the RA population) had done so in the last year and 
were considered an active user of Reumanet. Of this group, 110 patients (10 
percent of the RA population) were included in the SMOC (a flow diagram is 
provided as Supplementary Figure S1, available at Rheumatology Advances in 
Practice online).
Figure 1: Utilization of Reumanet beteen August 2017 and November 2019
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Patient characteristics of groups based on the usage of Reumanet
Table 1 shows the patient characteristics on 1 January 2019 of the total RA 
population, (, split into potential users and active users) and of the patient 
who participated in the SMOC between November 2017 and November 2019. 
Noteworthy is that the patients who use Reumanet and participate in the SMOC 
tend to be younger, more highly educated and have better health outcomes. 
Moreover, we observe that they seem to use more medication, consume more 
alcohol and are more likely to have stopped smoking.
Interrupted time series analyses of the introduction of Reumanet 
Bernhoven
The mean number of outpatient clinic visits in the total RA population in July 
2014 was estimated at 0.94 visits per patient per quarter (Figure 2). Prior to the 
introduction of the eHealth platforms there was an nonsignificant decreasing 
trend in the number of quarterly visits of -0.002 per quarter (95 percent 
confidence interval (CI)=[-0.123;0.009], p-value=0.766). After the introduction 
of the eHealth platform, the mean number of quarterly outpatient clinic visits 
decreased significantly each quarter by 0.027 (relative to the pre-interruption 
trend) (CI=[-0.045;-0.08], p-value=0.007).
Figure 2: outpatient clinic visits in the total rheumatoid arthritis population; The mean 
number of outpatient clinic visits per patient per quarter in the total rheumatoid arthritis popu-
lation between July 2014 and October 2019
2
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The decline in quarterly visits was even more prominent in the subgroup 
that eventually participated in the SMOC (Figure 3). In July 2014 they had a 
comparable mean number of outpatient clinic visits of 0.91 per patient per quarter. 
Prior to the introduction of the eHealth platform their mean number of outpatient 
clinics visits decreased nonsignificant by 0.003 per quarter (CI=[-0.009;0.003], 
p-value =0.297). After the introduction of the eHealth platform the trend for 
number of quarterly visits decreased significantly by 0.059 per quarter (relative 
to the pre-interruption trend) ([CI=-0.078;-0.040], p-value<0.001).
Figure 3: Outpatient clinic visits of the patients that would end up participation in the 
self-management outpatient clinic; The mean number of outpatient clinic visits per patient per 
quarter of the patients that would end up participation in the self-management outpatient clinic 
between July 2014 and October 2019.
The mean DAS28 of the total RA population in July 2014 was estimated at 
3.19 (Figure 4). Prior to the introduction of The eHealth platform there was an 
nonsignificant increase in the DAS28 of 0.014 per quarter (CI=[-0.006;0.034], 
p-value = 0.164). After the introduction of the eHealth platform the mean DAS28 
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The mean DAS28 of the subgroup of patients that would end up participating 
in the SMOC was estimated at 2.94 in July 2014 (figure 5). Their mean DAS28 
decreased significantly by 0.023 per quarter (CI=[-0.041;-.005],p-value=0.015) 
prior to the introduction of the eHealth platform. After the introduction of the 
eHealth platform the quarterly post-interruption trend of the DAS28 (relative to 
the pre-interruption trend) stayed approximately the same (CI=[- 0.036;0.047], 
P-value=0.962).
Figure 4: DAS28 of the total rheumatoid arthritis population; the mean disease activity score 
28-joints (das28) of the total rheumatoid arthritis population between July 2014 and October 2019
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Figure 5: DAS28 of the patients that would end up participation in the self-management 
outpatient clinic; the mean disease activity score 28-joints (das28) of the patients that would end 
up participation in the self-management outpatient clinic between July 2014 and October 2019
Discussion
After the implementation of Reumanet there was a significant decrease in 
number of outpatient clinic visits over time, without compromising disease 
control. Participation in the SMOC reduced the healthcare utilization even more 
without affecting the pre-existing decreasing trend in DAS28 present in this 
group. During this period both the percentage of potential Reumanet users and 
percentage of patients participating in the SMOC increased, while the percentage 
of patients regularly using Reumanet did not increase after the initial uptake. On 
average, the users of Reumanet were on average younger, more highly educated 
and had better health outcomes. This difference was even more evident in the 
participants of the SMOC.
Our real-world data matches positive results from clinical trials investigating 
self-management supported by eHealth applications and patient-initiated visits 
2
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for the treatment of rheumatic diseases.(14-18) We found a decrease in healthcare 
utilization after the implementation of telemedicine. This was accompanied by a 
clinically nonsignificant improvement in health outcome, showing at least non-
inferiority compared to care as usual. This adds to the growing body of evidence 
that concludes that telemedicine methods can safely be implemented in RA. 
These findings are also relevant in the treatment of other rheumatic diseases and 
even other chronic diseases. Due to SARS-CoV-2, many routine outpatient clinic 
visits have been cancelled and the expectation is that it can take years before 
things get back to normal. Therefore, eHealth applications can be used to support 
patients in their increased need for self-management, while patient-initiated visits 
can help select those patients that need to be seen at the outpatient clinic.
The inclusiveness of telemedicine remains an important issue. The goal of 
Reumanet was to improve patient engagement and to increase the number of 
patients that feels adequately equipped to perform self-management. To achieve 
this special attention was given to make the process as inclusive as possible 
during the implementation of Reumanet. These efforts led to an increase in the 
percentage of patients that was able to log in to the eHealth platform (from 55 to 
71 percent of the population). However, most of the active users engaged early 
on and the percentage that used the eHealth platform remained stable around 37 
percent. This illustrates that more efforts are needed in order to motivate more 
patients to participate in this self-management program. This low percentage 
corresponds to other real world data, were only 34 percent of the patients engaged 
in self-management.(13) At the same time, our data shows that it is a select 
group that participates in telemedicine, i.e. the younger, more highly educated 
patients with low disease activity. This matches findings from systematic reviews 
assessing the participants of patient-initiated follow-up and eHealth programs 
for the treatment of chronic diseases.(15, 28) This selective use of telemedicine, 
where eHealth is least used by the people who need it most, risks to widen the 
gap between those at risk of Social Health Inequalities (SHI) and the rest of the 
population.(28, 29) The effects of selective use of telemedicine on inequality and 
access to care should therefore be monitored. Different factors influence whether 
a patient will participate in self-management. For instance, patients with chronic 
rheumatic diseases perceive different levels of self-management as suitable for 
themselves and therefore do not always see themselves as partner in care.(30) 
Lack of information and lack of self-monitoring skills are perceived as barriers to 
perform self-management.(30) The high number of people with low health literacy 
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and low health skills (29 percent of the Dutch population) further complicates 
self-management.(31- 33) Therefore, further implementation of telemedicine 
requires good guidance, offering a tailormade approach, focusing on those ate 
risk of SHI.(29) Concurrently, we think that it is important to acknowledge that, 
at least at the moment, not all patients are capable of performing self-management 
and telemedicine. Adequate selection of which level of self-management can be 
expected of an individual patient is essential. In our opinion, this task is best 
performed by a nurse specialist affiliated with the SMOC. They often have more 
time and skills to explore patients’ conditions and needs. In addition, patients 
often experience a special relation of trust with their nurse specialist that allows 
for a tailormade approach aimed at tackling beforementioned barriers [25]. Using 
their relationship with the patient can help further increase the participation in 
self-management and telemedicine.
Interestingly, we noticed in recent months an increase in patients who 
actively enquired for the possibilities to perform telemedicine. This increase 
coincided with the SARS-CoV-2 pandemic in the Netherlands. Due to SARS-
CoV-2 there was an increase in internet use in the elderly, the group currently 
underrepresented in Reumanet users.(34). Simultaneously, the outpatient clinic 
had to partially close down, reducing the possibility for outpatient clinic visits. 
The fact that Reumanet was still readily available might have helped people 
overcome the barriers normally perceived. This change in patients participating 
in telemedicine should be closely monitored, since changes in the composition 
of the participating population could influence the effectiveness of telemedicine. 
Before telemedicine can be applied for the whole population, we should know the 
effectiveness of telemedicine in the groups currently not unlikely to participate.
This study evaluates the use of Reumanet and participation in the SMOC 
in a real-world setting. A strength of this study is that it offers the opportunity 
to assess which patients chose to use these programs in daily clinical practice. 
Participants of the program were clearly a self-selected group, which is currently 
the daily reality. (15, 28) As previously mentioned, efforts will have to focus 
on increasing the participants of the program. A limitation of observational 
data is the difficulty to assess causality of interventions. Because the study 
period comprises a lengthy period, external factors such as advances in treatment 
options or changes in treatment guidelines could potentially influence disease 
activity and, to a lesser extent, the number of hospital visits. An interrupted 
time series design is capable of identifying these underlying trends and isolates 
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the effect of the introduction of Reumanet. (35) By using the pre-interruption 
trend as control, the observed differences are more likely attributable to the 
studied interventions. This strengthens the confidence that the observed effect 
can be attributed to the introduction of Reumanet, especially because as far as 
we know during that time period no changes in other factors that could explain 
the underlying trend for healthcare utilization occurred.
In conclusion, the implementation of Reumanet, an eHealth platform aimed 
at supporting patients in their self-management need, resulted in less healthcare 
utilization, while maintaining disease control. Making use of patient-initiated 
visits in patients with stable disease activity resulted in an even larger reduction 
of healthcare utilization. Policymakers should use the momentum telemedicine 
has gained recently due to the SARS-CoV-2 pandemic, to further embed 
telemedicine in the healthcare system. Especially, with the expected cutbacks 
in mind, required due to the pandemic. Concomitantly, healthcare professionals 
need to remain vigilant to ensure that those currently unable to participate in 
telemedicine receive the care they need.
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These days, the use of biosimilars for the treatment of bio-naive patients is well 
established. However, the transition of patients being treated with a bio-originator 
to its biosimilar is still a topic of discussion. The main issue is which approach 
to use when initiating the non-medical transition. The first real-world examples 
contain both mandatory and non-mandatory approaches, resulting in a variety of 
acceptance and discontinuation rates. At this moment a non-mandatory approach, 
based on shared decision making, is preferred by international guidelines and 
the Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. 
However, clear definitions of mandatory and non-mandatory are lacking, as a 
result of which these terms may be wrongly used in some studies. This article 
aims to provide an overview of transition approaches used in the Netherlands, 
and how the approach used relates to acceptance and discontinuation rates of 
the biosimilar.
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Introduction
In 2015 the Dutch Medicines Evaluation Board updated their point of view on 
biosimilars.(1) From that moment on, patients being treated with a bio-originator 
could be transitioned to its biosimilar, if the patients were adequately monitored 
and well informed. Before that time, the Dutch Medicines Evaluation Board was 
of the opinion that patients should be kept on a biological medicinal product as 
much as possible, and strongly advised that biosimilars should only be prescribed 
to bio-naïve patients. As an addendum, the Federation of Medical Specialists 
(FMS) stated that patient should undergo only one switch between bio-originator 
and biosimilar and that repeated exchange between biological drugs had to be 
avoided.(2)
One of the fields where biologicals are widely prescribed is in the management 
of inflammatory rheumatic diseases. In 2015 more than 300 million euro was 
spent on this in the Netherlands alone, with an average of more than 10.000 euro 
per patient per year.(3)
In the Netherlands, prices for biologicals are negotiated at the hospital or at 
the regional level. Therefore, it varies among hospitals and regions, whether the 
bio-originator or the biosimilar gives the best value for money. A good example 
of this is the bio-originator for adalimumab, which after the expiration of its 
patent, is offered at an 80% discount.(4) These kinds of discounts influence 
both which biological bio-naïve patients receive and whether transitioning 
patients for non-medical reasons is feasible. Therefore, driven by their financial 
incentives, hospitals customize transitioning to fit their own situation. This 
results in hospitals that differ in whether they transition to biosimilars at all, 
which patients they offer transitioning to, and whether the transitioning is some 
sort of mandatory or not.
Biosimilars in the real world
Though international studies show that the acceptance rate of transitioning to 
biosimilars is in general quite high, 79 to 99 percent, (5-7) the retention rates 
after transitioning seem to differ between a blinded setting and data from daily 
clinical practice. A systematic review from 2018, investigating discontinuation 
after transitioning to biosimilars in inflammatory diseases, found a median 
discontinuation rate of 14% in open-label studies versus 7% in double-blinded 
settings.(8) This difference is hypothesized to be due to the nocebo effect (the 
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negative counterpart of the placebo phenomenon)(9) and attribution effects 
(the undeserved allocation of pre-existing or unrelated symptoms to the new 
medication)(10), though conclusive evidence for this is still lacking.(8, 11) At this 
point, most people believe that the nocebo effect can be reduced through better 
shared decision making) and patient information.(12-14)Therefore, emphasis 
is put on the process of transitioning, which offers an opportunity to inform 
patients, and “get them on board” with the process.
Because in the Netherlands each hospital customizes its transition, the Dutch 
situation gives us the opportunity to present an overview of different transitioning 
strategies and how these might influence outcome measures, like acceptance of 
transitioning, and the retention rate of treatment after transitioning.
Transitioning in the Netherlands
A survey conducted in all Dutch hospitals in 2016 found that 87% of the hospitals 
have some sort of policy in place regarding the use of biosimilars. Of these 
hospitals, about 50% indicated that they transition patients on bio-originator 
treatment to a biosimilar.(15) However, only a small number of hospitals has 
published data on transitioning to a biosimilar for the treatment of inflammatory 
diseases (Table 1).
Method of transitioning and the acceptance rate
In total 8 studies were identified (Table 1). However, even when data were 
published, it is not always stated whether the transition was mandatory or not, 
and when it is stated, there is no clear definition in what is called mandatory and 
non-mandatory. Therefore, we used the following two definitions and categorised 
the used approach by the description of transitioning given in the paper.
- Mandatory transition: patients were informed that a transition to biosimilar 
was happening. Following that, they were automatically transitioned. Only if 
they actively objected to the transition, they were not placed on the biosimilar.
- Non-mandatory transition: patients were informed of the possibility to 
transition. They were not transitioned, except when they actively agreed.
Mandatory transition
We identified four studies that used a mandatory approach, with an acceptance 
rate ranging from 96% to 100%.(7, 16-20) The studies by Smits et al.(16-18) 
and Schmitz et al. (19) did not state whether their transition was mandatory or 
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not, but after examining their approach, both seem to have been mandatory. 
The transitioning by Smits et al. took place after careful patient counselling 
while maintaining medical directives as per hospital protocol. Next to that, they 
stated that all patients were switched regardless of disease activity. Schmitz et 
al. communicated by letter to all patients that the transition was happening. The 
few people who had severe doubts regarding transitioning were persuaded by 
the physician to transition after a thorough explanation of the biosimilar concept. 
After this procedure all patients transitioned. Two other studies which used a 
mandatory approach, were performed by Tweehuysen et al. (7) and by Layegh et 
al.(20) They used a communication strategy developed by Tweehuysen et al. (21), 
which was later incorporated by the Dutch Association of Hospital Pharmacists 
(NVZA) into the NVZA “toolbox Biosimilars”, which is a practical guideline 
for transitioning to biosimilars.(21) Key elements of the strategy are: uniform 
communication; strict protocols; positive framing, tailored information and a wait 
and see approach if subjective health complaints arise. Tweehuysen et al. named 
their approach non-mandatory.(7) However, when examining the structured 
strategy more closely it becomes apparent that it better fits a mandatory approach. 
Their information letter stated that the hospital was transitioning to a biosimilar 
and that patients had the opportunity to ask questions to the pharmaceutical 
assistant regarding delivery of the biosimilar, during the next delivery of the 
medication. If a patient refused the transition, the reasons why the hospital was 
transitioning were stressed again. If a patient still refused, their rheumatologist 
would make contact within 3 days to discuss the transitioning. If after this 
consultation the patients still did not want to transition, the patient could continue 
with the bio-originator therapy.(21) It is very likely that the hurdles required to 
decline transition in this approach explains the near-complete acceptance.
Non-mandatory approach
Four other studies followed a non-mandatory approach and found acceptance 
rates varying from 77% to 87%.(22-25) Of these four studies, two clearly stated 
they tried to incorporate shared decision making in their transitioning method. 
In the first study, by Boone et al. (22), after informing patients by written 
documentation of the expectations following transitioning, patients were offered 
oral clarification by the patients’ treating physician or nurse practitioner when 
requested. Next to that, they formalised the procedure of giving informed consent 
by the patient, to emphasize that the change of treatment was introduced in a 
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shared decision making context.(22) In the second study, performed by Müskens 
at al. (23) all patients on bio-originators were informed by letter of the possibility 
to transition to biosimilars in the near future. During the next outpatient visit with 
their rheumatologist, the possibility to transition to a biosimilar was discussed 
with the patients treated with an etanercept bio-originator. If patients’ disease 
was not stable according to their rheumatologist, they were not eligible for 
transitioning. In this case change to another biological treatment was discussed. 
Patients had the opportunity to ask questions regarding biosimilars and the switch 
to a biosimilar. If patients agreed the transition was made, with the reservation 
that they could switch back to the originator at any time if they encountered 
difficulties with the biosimilar.
The only study that does not state that patients were informed by letter 
about the transition was the study by Binkhorst et al. (25) They only stated that 
patients were asked to transition to the biosimilar, implying the discussion took 
place during a consultation. The transition was initiated after patients had given 
informed consent.
Discontinuation of biosimilar therapy after transitioning
Most studies did not specify how they approached (subjective) health complaints 
after transitioning. Also, the duration of follow-up did differ across studies. 
Therefore it is difficult to assess differences in discontinuation rates and attribute 
this to the method of transitioning (Table 1).
However, when looking at the discontinuation rates, the drop in discontinuation 
between the two transitions conducted by Tweehuysen et al. (7, 24) is noteworthy. 
They found a lower discontinuation after the transition of etanercept, compared 
to the transition of infliximab (10% vs. 24% respectively after 6 months). A 
reason for the lower discontinuation rate was that they started using the earlier 
mentioned, mandatory, communication strategy in an attempt to prevent possible 
nocebo and attribution effects. Another aspect of the communication strategy 
was the “wait and see approach”. This meant that when patients experienced 
subjective health complaints, the physician discussed that this might be due to 
the nocebo effect. When the patients agreed, treatment with the biosimilar was 
continued. The study by Layegh et al, (20) which used the same, mandatory, 
approach, observed similar low discontinuation rates (13% after 24 months). 
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This approach differs strongly with the approach used by Müskens et al., (23) 
where it was clearly communicated before acceptance of the transitioning that 
patients were free to return to the originator if side effects occurred, or lack 
efficacy was perceived by the patients. This might be reflected in the higher 
discontinuation rate found by Müskens et al. (28% after 12 months).(23) 
Discussion
A brief overview of the published results from the Netherlands shows that 
acceptance of transitioning is generally high, with acceptance rates higher than 
77%. Most hospitals used a well-structured plan, with clear written patient 
information in combination with the possibility to consult with the treating 
physician or nurse practitioner. In several publications, the terms mandatory 
and non-mandatory transitioning were used. However, because these terms 
lack clear definitions, we could not use the term used by the authors. Based on 
the aforementioned mentioned definitions of a non-mandatory and mandatory 
transition, we re-categorised the different studies.
The main difference in acceptance rates for transitioning to biosimilars was 
explained by whether a hospital used a mandatory or non-mandatory approach. 
Mandatory methods resulted in the highest acceptance( 96-100%), but this came 
at the expense of the shared decision making process. There was large difference 
in discontinuation rates between studies, which was difficult to compare because 
of differences in follow-up time. However, there seems to be a trend for higher 
retention rates when a mandatory approach is used, especially in case it is 
combined with a “wait and see” approach..
The structured communication strategy from Tweehuysen et al., (21) 
as described above, resulted in near complete acceptance and relatively low 
discontinuation. Therefore the NVZA included it in the “toolbox biosimilars”. 
However, this approach is clearly mandatory and does not promote shared 
decision making between the patient and the physician. Personal communication 
from a small set of patients taking part in the transitioning from Etanercept 
originator to its biosimilar by Tweehuysen et al. (7) mentioned that they did not 
feel like they had a choice about whether or not to switch.
This accurately describes the tension between financial incentives and 
promoting shared decision making in case of transitioning to biosimilars for non-
medical reasons. In fact, there seems to be a trade-off between both forces that 
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manifests itself in a choice between a mandatory and non-mandatory approach. 
Patient awareness about biosimilars is generally low (26) and individual patients 
do not benefit from transitioning to a biosimilar. At the same time, the use of 
biosimilars is expected to bring great economic benefits on the societal level. 
(27, 28) The Task Force on the Use of Biosimilars to Treat Rheumatological 
Conditions captured this tension in two overarching principles (14):
1. “Treatment of rheumatic diseases is based on a shared decision-making 
process between patients and their rheumatologists”
2. “The contextual aspects of the healthcare system should be taken into 
consideration when treatment decisions are made”.
They concluded that “given the complex nature of all biopharmaceuticals, the 
treating clinician must be the only one to decide whether to prescribe a biosimilar 
in place of a bio-originator on a case-by-case basis with full awareness of the 
patient”.(14)
Current practice in the Netherlands, where most patients, are transitioned using 
an mandatory method does not seem to be adhering to these recommendations. 
Although maximal acceptance rates can be reached with the “toolbox 
Biosimilars”, the question should be asked how this tool influences the shared 
decision making process. As this tool does not promote shared decision making, 
it is interesting to evaluate the extent of shared decision making experienced by 
the patients.
At the same time, it should be evaluated what the effects of different transition 
approaches are on cost-reduction and healthcare resource utilisation. That 
lower medication prices will lead to lower medication cost on an individual 
base seems straightforward. But the scarce real-world data post-transition report 
increased inpatient readmission rates, increased steroid use, extra consultations, 
and increased biosimilar dosing.(29)This should warn us that a non-medical 
transitioning could finally lead to an increase in the total costs.
Though transitioning to biosimilars is relatively new, and real-world data are 
scarce, lessons learned from mandatory transitioning to generics bring warning. 
In the Netherlands, chronic patients are transitioned to generics for non-medical 
reasons, with 37% transitioning as often as three times or more on a yearly basis. 
78% of the patients find transitioning for non-medical reasons problematic, 34% 
felt worse after substitution and 23% had to undergo extra examination after 
substitution. At the same time, 40% of the respondents reported to suffer from 
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side effects of the new medication.(30) By taking shared decision making out of 
the transition process in the field of biologicals, a similar experience might be 
observed here as well.
At the moment biosimilars are being prescribed for the treatment of 
inflammatory rheumatic diseases in both bio-naïve patients and in patients 
undergoing treatment with the bio-originator. There is a lot of heterogeneity 
in the approaches used for initiating the transition to biosimilars, but also in 
how subjective health complaints are handled when they arise. Lack of a clear 
definition of what is a non-mandatory transitioning makes it impossible to blindly 
copy the wording used by authors. However, in the Netherlands, at present, 
there seems to be a preference for a mandatory approach resulting in higher 
acceptance rate and lower discontinuation rates. This comes at the expense of 
the shared decision making process. It seems contradictory that policy makers, 
who are often advocating SDM, implement a policy that is primarily aimed at 
maximizing cost savings.
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The aim was to study the effect of non-mandatory transitioning from etanercept 
originator to etanercept biosimilar on retention rates in a setting promoting 
shared decision-making.
Methods 
In 2016, all patients treated with etanercept originator and stable disease at the 
Rheumatology department in Bernhoven were offered transitioning to etanercept 
biosimilar by an opt-in approach. A historical cohort of patients treated with 
etanercept originator in 2015 was identified as the control group. Etanercept 
discontinuation was compared between the cohorts using Cox regression. To 
study the nocebo effect, reasons for discontinuation were categorized into 
objective reasons (e.g. laboratory abnormalities, increase in swollen joint count, 
allergic reaction) and subjective health complaints (symptoms perceptible only 
to the patient, e.g. tiredness, arthralgia). An adjusted Kaplan–Meier curve for 
retention of the etanercept biosimilar was made, censoring subjective health 
complaints as the reason for discontinuation.
Results 
Seventy of the 79 patients eligible for transitioning agreed to transition (89%). 
The one-year crude retention rate of etanercept in the transition cohort was 
73% (95% CI: 0.62, 0.83), compared with a retention rate of 89% (95% CI: 
0.81, 0.95) in the historical cohort (P = 0.013). This resulted in a higher risk of 
treatment discontinuation in the transition cohort (adjusted hazard ratio = 2.73; 
95% CI: 1.23, 6.05, P = 0.01). After adjusting for the nocebo effect, the cohorts 
had comparable retention rates (86 vs 89%, P = 0.51).
Conclusion 
Non-mandatory transition from etanercept originator to its biosimilar using an 
opt-in approach in a setting promoting shared decision-making resulted in a 
higher discontinuation of etanercept compared with the historical cohort. This 
could be attributed largely to the nocebo effect.
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Introduction
In January 2016, the first etanercept biosimilar (EB) was approved by the 
European Medicines Agency [1]. At that point, a large randomized clinical trial 
had shown that the efficiency of the EB was comparable to that of the etanercept 
originator (EO) in a blinded setting [2–4]. In many countries, substitution of 
a bio-originator with a biosimilar was assumed for treatment of bio-naïve 
patients [5]. However, non-medical transitioning from the bio-originator to its 
biosimilar was debatable, and this discussion is still ongoing. No consensus has 
been reached about how and when to transition [6–8]. A recent study looked at 
the effect of open-label transitioning from EO to EB on the retention rates of 
etanercept in a mandatory setting. That study showed a lower retention rate for 
etanercept after transitioning to EB compared with a historical cohort being 
treated with the EO. The reasons for EB withdrawal were mainly subjective and 
were hypothesized to be attributable to the nocebo effect [9]. The nocebo effect 
is the counterpart of the placebo effect. The placebo effect can occur when there 
is a positive perception of the treatment being administered, whereas the nocebo 
effect may occur when there is a negative perception. Contrary to the placebo 
effect, the nocebo effect leads to a more negative outcome [10]. The current 
hypothesis is that by improving the shared decision-making process, educating 
the medical professional in techniques of communication and improving their 
ability to interact with patients, in addition to providing patients with structured 
information, the nocebo effect can be reduced and retention rates improved 
[11–14]. However, this has not yet been demonstrated in the transitioning to 
biosimilars. The importance of shared decision-making and adequate patient 
information is stressed in the 2015 statement of the Dutch Medicines Evaluation 
Board declaring that ‘the exchange between biologic medicines is permitted, 
but only if adequate clinical monitoring is performed and the patient is properly 
informed’ [11]. This is in line with current guidelines promoting shared decision-
making for the treatment of rheumatoid arthritis (RA) [12] and the findings of 
the Task Force on the Use of Biosimilars to Treat Rheumatological Diseases, who 
stated that ‘Treatment of rheumatic diseases is based on a shared decision-making 
process between patients and their rheumatologists’ [7]. Therefore, in line with 
current views regarding shared decision-making [7, 12] and in an attempt to 
counter the nocebo effect [13], a non-mandatory transition in a setting promoting 
shared decision-making might be preferred. The aim of this observational study 
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was to assess the one-year retention of EB after open-label non-mandatory 
transitioning from EO in patients with stable inflammatory rheumatic disease 
in a setting promoting shared decision-making. Secondary analyses aimed to 
assess the acceptance rate of the non-mandatory transition [1] and the influence 
of the nocebo effect on the retention of the EB [2].
Methods
Study design and method of transition
This observational study assessed the open-label nonmandatory transition from 
EO to EB at the Rheumatology Department of Bernhoven, a general hospital in 
Uden, in the south of The Netherlands. Since 2015, Bernhoven has been actively 
promoting the shared decision-making strategy, in an attempt to improve shared 
decision-making in the hospital [14]. The transition was part of the usual care 
delivered at Bernhoven and, as such, shared decision-making was an important 
part of the transitioning to the EB. Firstly, all health professionals of the 
outpatient department were informed about the transition process and educated 
about the biosimilars. At the same time, all patients receiving EO were informed 
by a standardized letter containing information on both the biosimilar and the 
proposed transition process to EB. Secondly, the possibility of transitioning was 
discussed between the patient and the rheumatologist during the next outpatient 
visit. This gave patients the opportunity to ask questions regarding biosimilars 
and transitioning to a biosimilar. At the same time, it gave the rheumatologist 
time to assess whether the patient’s disease was stable. In addition, it was once 
more stressed that patients could return to treatment with the originator if they 
encountered difficulties with biosimilar treatment. An opt-in approach was used, 
whereby patients had to agree actively to transition, before they were transitioned 
to the EB. If the patient still had questions regarding, for instance, the transition 
or administration of the biosimilar, a consultation with the nurse specialist was 
planned to address these and any other questions.
Patients
As part of usual care, patients at the Rheumatology Department of Bernhoven 
were proposed to transition to EB if they met the following disease-related 
criteria: they were diagnosed with RA, according to the 2010 ACR/EULAR 
criteria [15], or with either psoriatic arthritis (PsA) or ankylosing spondylitis 
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(AS), according to the 2009 Assessment of Spondyloarthritis International 
Society criteria [16]; they were being treated with EO (50 mg in a prefilled pen 
or syringe) between 1 June 2016 and 22 October 2017; and they had stable disease 
activity according to the physician’s opinion. 
Figure 1: Flowchart of follow-up in the transition cohort and the historical cohort.
EO treated patients (n=84)
Agreed to transition to EB (n=70)
Transition cohort (n=70)
Analyses at one year follow-up
• Censored (n=1)
• Stopped EB due to remission (n=1)
• EB continued (n=50)
• EB discontinued (n=19)
• Ineffective (n=4)
• Adverse event (n=8)
• Ineffective a& adverse event (n=3)
• Others (n=4)
EO treated patients (n=84)
EO treated patients (n=89)
Historical cohort (n=89)
Analyses at one year follow-up
• Censored (n=6)
• Stopped EO due to remission (n=3)
• Moved away (n=3)
• EO continued (n=73)
• EO discontinued (n=10)
• Ineffective (n=8)
• Others (n=2)
EO= Etanercept originator; EB= Etanercept biosimilar
All patients agreeing to transition to EB were included in the transition cohort. 
All patients being treated with the EO at the same department on 1 June 2015 
were identified as the historical cohort. All procedures were performed in 
accordance with the ethical standards of the institutional and national research 
committee and with the 1964 Declaration of Helsinki and its later amendments 
or comparable ethical standards. According to Dutch regulation, this study did 
not require ethical approval because only data used for daily clinical practice 
were collected. All patients had provided written informed consent for the use 
of their data for scientific purposes at an earlier time point.
Data collection
Data regarding demographics, disease and treatment were recorded at the time 
of inclusion and during the follow-up visits performed in usual care in the year 
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after transition. Disease activity was measured with the DAS 28 joints (DAS28) 
for RA and PsA. The BASDAI was measured for AS. Reasons for etanercept 
discontinuation were documented by the rheumatologists in the electronic patient 
records. Reasons for discontinuation were categorized into objective reasons (e.g. 
laboratory abnormalities, increase in swollen joint count, allergic reaction) and 
subjective health complaints (a descriptive term for symptoms perceptible only 
to the patient, e.g. tiredness, arthralgia).
Statistical analyses
All continuous variables were expressed as the mean with S.D. or median with 
range, depending on distribution, and tested with Student’s two-tailed t-test or 
Wilcoxon’s rank sum test, respectively. All categorical variables were expressed 
as proportions and analysed using a χ2 test.
Firstly, the acceptance of non-mandatory transitioning was studied. 
Differences in baseline characteristics between patients accepting and patients 
declining the transition to biosimilar were assessed.
Secondly, the one-year retention rate of etanercept was explored in both the 
transition cohort and the historical cohort using a Kaplan–Meier curve, and 
the difference in retention rate distributions was tested using the log-rank test. 
Patients who discontinued treatment because they achieved clinical remission 
were not coded for an event but were censored at the time of discontinuation.
Thirdly, the hazard ratio (HR) of treatment discontinuation between the 
transition cohort and the historical cohort was calculated using Cox regression. An 
adjusted HR of treatment discontinuation was calculated to account for possible 
baseline differences [in age, sex, diagnosis, treatment duration categorized in 
two groups (>1 year and 1 year), dose interval, combination therapy and CRP 
level] between the transition cohort and the historical cohort using a multivariate 
Cox regression. A robust variance estimator was applied in the Cox regression to 
account for repeated subjects (i.e. patients included in both the transition cohort 
and the historical cohort). To address missing values, especially for CRP level, 
multiple imputation was used. The fully conditional specification method was 
used because this allows any missing data pattern, and the cumulative hazard 
instead of time to retention was used in the imputation model as advised in the 
literature [17].
Fourthly, to study the possible nocebo effect in the transition cohort, an 
adjusted Kaplan–Meier curve for the retention of the EB was made, censoring 
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subjective health complaints as a reason for discontinuation. Subjective health 
complaints were defined as worsening of disease perceived by the patient, in the 
absence of clinical signs of arthritis according to the rheumatologist or change 
in the disease activity score. The reasons for discontinuation and the course of 
action after discontinuation were also described.
Additional (sub)analyses are presented in the Supplementary Material and 
Supplementary Table S1, available at Rheumatology Advances in Practice online.
The analysis for this paper was generated using SAS software, v.9.2 with v.9.4 
of the SAS System for Windows (copyright 2011 SAS Institute Inc.). Values of 
P < 0.05 were considered as statistically significant.
Results
Patients
A total of 84 patients were being treated with EO (50 mg) between 1 June 
2016 and 23 October 2017 (Fig. 1). Of these patients, five did not have a stable 
disease activity according to their rheumatologist and were therefore not eligible 
for transitioning. Of the 79 patients who were eligible, 70 (89%) accepted 
transitioning. As the historical cohort, 89 patients being treated with EO (50 
mg) on 1 June 2015 were identified. A total of 56 patients were included in both 
the transition cohort and the historical cohort. Patient, disease and treatment 
characteristics of the transition cohort and the historical cohort are given in 
Table 1. Patients accepting and patients declining the transition showed similar 
baseline characteristics.
Biosimilar discontinuation
The discontinuation of etanercept is shown in Fig. 2. The one-year crude 
retention rate of Etanercept in the transition cohort was 73% (95% CI: 0.62, 
0.83), compared with a retention rate of 89% (95% CI: 0.81, 0.95) in the historical 
cohort (P = 0.013). Therefore, patients in the transition cohort had a higher risk of 
treatment discontinuation (HR = 2.56; 95% CI: 1.19, 5.49, P = 0.016). Adjusting 
for baseline differences and taking repeated measures into account did not 
significantly alter the risk of treatment discontinuation (adjusted HR = 2.73; 95% 
CI: 1.23, 6.05, P = 0.01).
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Age, years (mean ± SD) 58 ± 14 70 56 ± 19 89
Female sex, % 51 36 55 49
Diagnosis
RA, % 69 48 73 65
PsA, % 16 11 11 10
AS, % 16 11 16 14
Disease characteristics
Disease duration, years (median (IQR)) 10 (6-14) 67 9 (6-17) 87
CRP mg/liter (median (IQR)) 2 (2-4) 63 2 (2-4) 63
DAS28 (median (IQR)) 2.7 (2.2-3.7) 39 3.0 (2.4-3.8) 47
RF positive, % 72 31 71 42
Anti-CCP, % 71 30 73 40
BASDAI (median (IQR)) 1.4 (1.2-2.6) 6 2.3 (1.3-3.9) 7
HLAB27 positive, % 54 7 62 8
Treatment characteristics
No. of previous biologics (median (IQR)) 0 (0-0) 70 0 (0-0) 89
ETN treatment duration, years (median (IQR)) 5 (2-8) 68 4 (2-7) 88
csDMARD combination therapy, % 52 70 48 89
ETN dose interval, days (median (IQR)) 7 (7-7) 70 7 (7-7) 89
SD= Standard Deviation; RA= Rheumatoid Arthritis; PsA= Psoriatic Arthritis; AS= Ankylosing 
Spondylitis IQR= Interquartile Range; DAS28= Disease Activity Score 28 joints RF= Rheumatoid 
Factor; Anti-CCP= Anti–Citrullinated Protein Antibody; BASDAI= Bath Ankylosing Spondylitis 
Disease Activity Index; HLAB27= Human Leukocyte Antigen B27; ETN= Etanercept; 
csDMARD= Conventional Synthetic Disease-Modifying Antirheumatic Drugs
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Figure 2. Kaplan-Meier curve showing the discontinuation of etanercept in the historic cohort 
and the transition cohort
Figure 3: adjusted Kaplan-Meier curve.
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Table 2. Health complaints and reasons for discontinuation in the transition cohort and the 
historical cohort.




Objective health complaints 10 10
Clinical worsening 1 8
Clinical worsening & painful injection 1 -
Diarrhea 1 -
Infections 1 -
Mucositis and clinical worsening 1 -
Hypersensitivity reaction 1 -
Stopping of medication due to scheduled surgery - 1
Stopping of medication due to terminal illness 2 1
Switch to other medication due to AS 1 -
General decline 1 -
Subjective health complaints 9 -
General discomfort/overall malaise 2 -
Increased tiredness 1 -
Arthralgia without clinical sign of arthritis 3 -
Muscle aches in arms 1 -
Tingling in hands and feet 1 -




To assess the influence of the nocebo effect, the reasons for stopping treatment 
were analysed. Reasons for treatment discontinuation in the 19 patients who 
discontinued etanercept treatment in the transition cohort and the 10 patients who 
discontinued etanercept treatment in the historical cohort are specified in Table 2. 
In the historical cohort, all 10 patients had objective reasons for discontinuation. 
Eight patients (80%) had clinical worsening of the disease, assessed by a DAS28 
of >4.0, one patient (10%) had to stop owing to scheduled surgery, and one 
patient (10%) had to stop owing to a terminal illness. In the transition cohort, 
seven patients (37%) reported clinical worsening of the disease. However, four 
of those did not have any clinical signs of worsening of disease activity. In total, 
nine patients (47%) discontinued because of subjective health complaints. This 
amounted to a nocebo response of 13% in the transition cohort. After adjusting 
556700-L-bw-Muskens
Processed on: 29-4-2021 PDF page: 63
63 
Transitioning to a biosimilar and shared decision-making 
for subjective reasons for discontinuation, the transition cohort and the historical 
cohort had comparable retention rates (86 vs 89%, P< 0.51; Fig. 3). Only one 
serious adverse event was reported in the transition cohort. The serious adverse 
event seemed to be a drug hypersensitivity reaction after transitioning. During 
follow-up, this reaction also occurred without any treatment, suggesting a cause 
other than the biosimilar. Of the patients who discontinued EB treatment in 
the transition cohort, 12 patients (63%) returned to treatment with the EO, two 
patients (11%) switched to another biologic, and five patients (26%) discontinued 
biologic treatment altogether.
Discussion
This study focused on a non-mandatory open-label transition from EO to EB in 
a setting promoting shared decision-making. Acceptance of the transition using 
an opt-in method was high (89%). However, after transitioning there was higher 
discontinuation of etanercept in comparison to discontinuation in a historical 
cohort in the same setting. This difference in discontinuation was mainly driven 
by subjective health complaints. During one-year follow-up, the effectiveness of 
the EO and the EB was similar.
One of the strengths of this design is that real-world data were collected and 
assessed. This offered the possibility for studying the retention rates in a setting 
promoting shared decision-making and comparing these with those of the bio-
originator in the same setting. A weakness of the design is that the control group 
consisted of a historical cohort. Therefore, calendar time bias could occur, with 
stricter adherence to the treat to-target principle in the later time period. This 
could lead to higher discontinuation of the biologic therapy in the transition 
cohort. Given that patients in the transition cohort were selected on the basis of 
stability of the disease, this could have led to selection bias, whereby the selected 
group was less likely to discontinue, because unstable patients are more likely 
to discontinue treatment [9, 18]. If this effect occurred, the observed difference 
in discontinuation of etanercept is an underestimate of the true difference in 
discontinuation.
There is a large heterogeneity in the methods used to transition patients and the 
way in which patients are informed about the transition [19]. There are differences 
regarding whether the approach is mandatory or nonmandatory and whether an 
opt-in or an opt-out method is used. These differences in approach are relevant, 
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because they are hypothesized to influence acceptance rates and retention 
rates [15]. In our study, we tried to empower patients using a non-mandatory 
opt-in method, whereby patients were involved in the decision to transition and 
in the decision to (dis)continue biosimilar treatment. It is thought that such a 
method might lead to higher retention rates by countering the nocebo effect, 
and at the same time it fits with shared decision-making [7, 13, 19]. However, 
we observed an increased discontinuation of biologic therapy after transition to 
the biosimilar. This increased discontinuation appears to have been influenced 
by our transition method, which offered patients the option to return to the 
originator if they encountered difficulties with the biosimilar. This assumption 
is strengthened by the high number of patients with subjective health complaints 
who discontinued treatment. Of the patients who discontinued treatment, 63% 
returned to the originator, instead of switching to another biological, because no 
signs of increased disease activity were present. In these cases, complaints were 
possibly attributable to the nocebo effect, and restarting the originator therapy 
was likely to be successful.
After adjusting for the nocebo effect, the retention rate in the transition 
cohort increased from 73 to 86% and was comparable to the retention rate in 
the historical cohort. This observed incidence of discontinuation because of 
the nocebo effect of 13% in the transition cohort matches the 13% incidence 
of the nocebo effect observed in an earlier study that transitioned patients with 
immune-mediated inflammatory diseases from the infliximab bio-originator 
to its biosimilar on the basis of shared decision-making [20]. During the same 
time period as our study, a study was performed by Tweehuysen et al. [18], 
which was similar to ours in design but differed in the way in which patients 
were informed. They used a more directive approach, informing the patients that 
transition was necessary, while at the same time using a ‘wait and see’ approach, 
if patients experienced subjective health complaints. As can be expected, a lower 
discontinuation rate after transitioning was found. After 6 months, the retention 
rate in the transition cohort compared with the historical cohort was 90 vs 92% 
[18].We observed a comparable small difference in one-year retention rates 
between our transition cohort and the historical cohort, after adjusting for the 
discontinuation attributable to the nocebo effect. These findings imply that our 
method of transitioning does not seem to counter the nocebo effect sufficiently. 
On the contrary, the information given by the health-care personnel and the 
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informed consent procedure could, instead of reducing nocebo effects, introduce 
these negative feelings in the patient and facilitate the nocebo response.
The above-mentioned study by Tweehuysen et al. [18] found an acceptance 
rate of 99% using an opt-out approach, whereby patients were transitioned 
to the biosimilar unless they actively objected, in contrast to our acceptance 
rate of 89% using an opt-in approach. These results suggest that the method of 
transitioning and doctor–patient communication also influence the acceptance 
rate of transitioning.
These findings make the ongoing discussion about selective non-disclosure of 
information to patients to negate the nocebo effect relevant [21–23]. It has been 
hypothesized that a paternalistic non-disclosure of information might decrease 
nocebo-induced adverse events and lead to higher retention rates [19]. Current 
evidence, where a more directive approach results in higher acceptance rates and 
retention rates, supports these hypothesis [18]. Therefore, using a more directive 
approach seems a logical step when maximizing cost reduction, by maximizing 
biosimilar utilization, is the primary goal. However, this approach does not 
take the opinion of the patient seriously and is directly contrary to the latest 
guidelines for the treatment of RA and the findings of the Task Force on the Use 
of Biosimilars to Treat Rheumatological Diseases, both of which promote shared 
decision-making [12]. Therefore, it would be interesting to study the satisfaction 
of patients with these different approaches.
Our shared decision-making approach used for transitioning from EO to EB 
resulted in a lower retention rates of EB compared with a historical cohort. At 
the same time, effectiveness was comparable. A difference in retention rates was 
caused by an increase in subjective health complaints. The acceptance rate and 
retention rate observed using a shared decision-making approach were lower 
compared with those observed using a more directive approach. These findings 
contradict the hypothesis that more patient involvement in decision-making and 
patient empowerment reduce the nocebo effect and improve retention rates. 
Furthermore, it implies that there is a tension between maximal cost reduction 
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The market entry of biosimilars is expected to bring budgetary relief. Our 
objective was to determine how the introduction of biosimilars influences 
medication cost in patients with rheumatoid arthritis and which patients gain 
access to biologicals due to the availability of biosimilars.
Methods 
Using hospital data of patients with rheumatoid arthritis between 2014 and 2018, 
an interrupted time series was performed. The interruption in the time series 
was placed at June 2016, i.e., the introduction of the etanercept biosimilar. The 
changes in trends for rheumatic medication cost before and after the interruption 
were measured. Secondary analyses focused on explaining these trends.
Results 
In the first quarter after the interruption, there was a decrease in total cost for 
biologic users of €-63020 (CI=[€-96487;-€-29553]; P=0.001). The post-interruption 
trend did not differ from the pre-interruption trend (CI=[-€6695;€6715]; P=0.998) 
and after three quarters the medication cost were back at the interruption level. 
After the interruption, the average cost per biologic user decreased by €-370 
(CI=[€-602;€-138]; P=0.005), followed by a quarterly decrease (relative to the pre-
interruption trend) (CI=[€-86;€-14] P=0.010), bending the average cost curve. The 
percentage of patients being treated with biologics increased in post-interruption 
by 0.50 percentage points quarterly (CI=[0.38-0.62]; P<0.001). Also the average 
age at the start of the first biologic increased after the interruption (p=0.057).
Conclusions 
The average cost per patient treated with biologicals decreased after the 
introduction of biosimilars with a persistent trend. However, the budgetary relief 
due to market entry of biosimilars vanished quickly due to an increase in patients 
treated with biologics.
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Introduction
Cost containment in health care is a big issue in Western Countries. However, 
health care expenditures keep on growing. It is generally believed that when 
a patent on pharmaceuticals expires, this leads to a drop in health care cost. 
Whether and how this actually occurs in the Netherlands will be investigated in 
this paper. All expensive medication in the Netherlands is financed through the 
hospital, and costs are therefore part of Medical Specialist Care (MSC). However, 
at this point the growth of expensive medication cost exceeds the growth rate of 
the MSC as a whole. This means, given a fixed budget, that the expenditure on 
expensive medicines is displacing other care.(1)
Here the focus is on biologic medication of which the patent period has 
expired. It is anticipated that a decrease in prices for expensive medication, 
initiated through the availability of unpatented biologics, so called biosimilars, 
will lead to lower total costs and create budgetary relief.(1) Biosimilars are 
biotherapeutic products (biologics) that are similar in terms of quality, safety and 
efficacy to an already licensed reference biotherapeutic product (bio-originator).
(2) However, biosimilars have a significantly lower price and thereby induce price 
competition between bio-originator and biosimilar producers which is assumed 
to result in cost savings and finally bend the (total) cost curve.
These expectations, regarding the predicted budget impact of biosimilars, 
are based on many studies performed in the build-up to patent expiration of bio-
originators.(3-8) All these studies predicted a cost saving. The amount of cost 
saving predicted differed, depending on the acquisition cost of the biosimilar 
drug,(8) the initial number of patients being treated with biologic therapy,(8) the 
number of biosimilars being available,(6) and the uptake of biosimilar use.(5)
One of the fields where the introduction of biosimilars is predicted to generate 
savings, is the treatment of rheumatoid arthritis (RA).(5, 6, 8) At this point, 
biosimilars for the TNF-Alfa blockers (a subgroup of biologics) adalimumab, 
etanercept and infliximab have been approved by the European Medicines 
Agency.(9) The expectations for biosimilars with regard to cost saving are high. 
For example, the chief executive of NHS recently announced that he expects the 
use of an adalimumab biosimilar to free up 300 million pounds (340 million euro) 
in the UK, which can be invested in patient care in general.(10) To assess the real-
world impact of biosimilars, the impact of infliximab and etanercept biosimilars 
on the biologic disease-modifying antirheumatic drug (bDMARD) budget in 
5
556700-L-bw-Muskens
Processed on: 29-4-2021 PDF page: 72
72
Chapter 5
the UK was studied.(11) The main finding of that study was that introduction of 
biosimilars indeed resulted in lower medication prices due to price reduction of 
both the bio-originators and the biosimilars. However, their data also showed an 
increase in the overall utilization of biologics, though they did not explain this 
finding further. Their data showed that this increased utilization of bDMARDs 
outweighed the price reduction achieved through the introduction of biosimilars. 
Therefore, no net savings were achieved even though prices for bDMARDs 
dropped.
Similar observations were made in the Netherlands, in a recent report based 
on real-world data from the Dutch Healthcare Authority (NZa). They observed 
a similar reduction in individual prices for existing expensive medication, 
accompanied with an increase in utilization of these expensive medications. 
Therefore the total cost for these medications increased.(1) For TNF-alfa blockers 
specifically they observed an increase of 11% in the volume of patients using 
bDMARDs.(1)
Both the NZa report(1) and the UK study(11) show an increase in the volume 
of bDMARDs for the treatment of RA. However, because these studies were 
based on national declaration data, they did not report on the mechanisms behind 
it nor did these studies report on which patients gained access to bDMARDs. This 
evokes several questions from the perspective of a care provider. Is there a change 
in the percentage of patients using bDMARD therapy after the introduction of 
biosimilars? Are demographic and medical characteristics of patients receiving 
bDMARD treatment able to explain the potential change over time?
Our main aim was to study the impact of market entry of an etanercept 
biosimilar on medication cost in the biologic users of the RA population in 
a general hospital in the Netherlands. Secondary objectives were aimed at 
explaining the trends found.
Methods
Design
We studied the price effect of the introduction of biosimilars in RA using a 
single center interrupted time series design. The trends of total medication 
cost in bDMARD users and medication cost per patient using bDMARDs 
were compared before and after the introduction of an etanercept biosimilar at 
the Department of Rheumatology at Bernhoven in June 2016. Bernhoven is a 
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medium-sized hospital in the south of the Netherlands that serves as a secondary 
referral centre in the region. This gives Bernhoven a case-mix of patients that is 
representative for general hospitals in the Netherlands.
From June 2016 onwards all patients who initiated etanercept treatment were 
treated with the biosimilar. The criteria for eligibility for bDMARD treatment 
in the Netherlands did not change during the study period: a Disease Activity 
Score 28 joints (DAS28) > 3.2 after treatment failure with at least 2 conventional 
synthetic disease-modifying antirheumatic drugs (csDMARDs), including 
methotrexate in a dose of 25mg/week. (12) Since transitioning to a biosimilar is 
allowed in the Netherlands, all patients with inflammatory rheumatic diseases 
treated with the etanercept originator in Bernhoven were invited to transition to 
the biosimilar. About 87 percent of these patients accepted the transition, with a 
one-year retention rate of 72 percent .(13) These rates fall well within the range 
observed by other studies in the Netherlands.(13)
During the study period an infliximab biosimilar became available at the 
hospital. However, as the prescription of infliximab for the treatment of RA 
is low in the Netherlands in general, only 10 patients received treatment with 
infliximab during the study period in Bernhoven , i.e. less than 4 percent of the 
DMARD users. Therefore, we deemed the influence of the introduction of the 
infliximab biosimilar negligible and focused on the introduction of the etanercept 
biosimilar.
Ethics
All patients gave their informed consent for use of their medical data for scientific 
purpose at an earlier point in time. Ethical approval was not necessary for this 
study, given the registry of common practice care based data collection.
Inclusion criteria
All patients with RA being treated at Bernhoven from June 1, 2014 up till June 
1, 2018 were included in the analysis, providing a representative sample for the 
Dutch RA population. All patients included had been diagnosed with RA by 
their rheumatologist according to the ACR 2010 criteria.(14)
Data and instruments
Data on medication use of all patients with RA were collected using the electronic 
medical record system of Bernhoven. Information regarding the specific use of 
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the etanercept bio-originator or the etanercept biosimilar was verified via the 
pharmacy of Bernhoven.
The following demographic and medical characteristics were collected: age, 
gender, rheumatoid factor (RF) positivity, anti-cyclic citrullinated peptides (anti-
CCP) positivity, disease duration, disease activity. The DAS28 was used as a 
measure of disease activity (score between 0 and 10; higher score indicates higher 
disease activity).(15)
The quarters followed a 3 monthly sequence starting on the 1st of June 2014. 
For each quarter the sample consisted of all patients with an active diagnosis of 
RA at the department. Patients were categorised as bDMARD user if they were 
treated with a bDMARD during that quarter.
Rheumatic medication cost
Rheumatic medication cost (RMC) was defined as the cost for non-steroidal 
anti-inflammatory drugs, csDMARDs, bDMARDs, and glucocorticoids.
In the Netherlands bDMARDs are paid for through the hospital budget, and 
prices are negotiated with the pharmaceutical company per hospital. Therefore, 
information on the price of all bDMARDs was obtained from the pharmacy of 
Bernhoven to account for the negotiating bonus. These prices are confidential 
and therefore not disclosed here. During the study period the hospital negotiated 
a discount for the etanercept biosimilar.
Other medication, is directly reimbursed by health insurance companies. 
These prices are collected through the website www.medicijnkosten.nl as 
recommended by the Dutch guideline for cost-effectiveness research.(16)
Analyses
A single center interrupted time series analysis is used that estimates the 
coefficients by ordinary least squares regression with Newey–West standard 
errors to handle autocorrelation in addition to possible heteroscedasticity in the 
data. In general the regression model assumes the following form:
RMCt is the aggregated rheumatic medication cost variable measured at each 
quarter t since June 1, 2014, Tt is the time since the start of the study, Xt is a 
dummy variable for the moment of interruption and XtTt is an interaction term. Of 
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interest are β2 and β3 which respectively show the immediate price effect at time 
of interruption and the difference in trend between pre- and post-interruption. 
(17) Autocorrelation in the error distribution is tested by the Cumby–Huizinga 
general test for autocorrelation. Depending on the outcome of this test one or 
more lags are added to the model above. The interruption in the time series 
(quarterly intervals) was placed at June 1 ,2016, i.e., the drop in price due to the 
introduction of biosimilar(s). Time series were run to assess the RMC, first in the 
total RA population, then in bDMARD users only. Demographic and medical 
variables were added to the model to explain the trends found. The total RMC of 
the total RA population was adjusted for bDMARD cost to study the cost of the 
other rheumatic medication (i.e. csDMARDs and glucocorticoids). In a separate 
analyses, the average cost per patient in bDMARD users was adjusted for the 
bDMARD dosage, to assess whether bDMARD dosage influenced the average 
rheumatic medication cost per patient. The bDMARD dosage was standardized 
as percentage of the daily defined dosage.(18) An additional time series was 
run to assess the percentage of biological users, instead of the RMC, in the RA 
population over time. To take into account possible demographic differences 
between patients using bDMARDs in the pre-interruption and post-interruption 
period the RMC model(s) was run with the following covariates: BMI, age, and 
gender (adjusted model I). Similarly, it was investigated whether RA specific 
disease parameters differed between patients using bDMARDs in the pre- 
and post-interruption period including: RF positivity, anti-CCP positivity, age 
at diagnosis, age at start of first biologic and DAS28 at start of first biologic 
(adjusted model II). Analyses were done in STATA 15.1.
Results
Patients characteristics of the RA population
Between June 1, 2014 and June 1, 2018, the RA population in Bernhoven increased 
from 640 to 961 patients. The patient characteristics of the RA population and 
subgroup of bDMARD users at the 1st of June 2016 are shown in table 1. At that 
moment, 17 percent of the population was treated with bDMARDs. By June 
2018, 20 percent of the population used a bDMARD and 28% percent of those 
were treated with the etanercept biosimilar.
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Table 1 Patient characteristics of the total population and the subgroup of patients using biologic 
disease modifying anti-rheumatic drug in June 2016
Characteristics RA population bDMARD users
827 N 141 N
Patient characteristics
Age in years, mean (SD) 63 (14) 827 58 (14) 141
Disease duration in years, mean (SD) 8 (8) 824 11 (9) 141
Female gender, % 65 541 70 99
DAS28 3.1 (1.2) 630 3.3 3.3 (1.5)
RF positive, % 57 392 56 69
Anti-CCP positive, % 55 378 63 78
BMI, mean (SD) 27 (10) 432 26 (5) 58
RA= Rheumatoid arthritis; bDMARD= Biologic disease modifying anti-rheumatic drug; 
DAS28= Disease Activity Score 28-joints; RF=Rheumatoid Factor; Anti-CCP= anti-cyclic 
citrullinated peptides; BMI=Body Mass Index; SD= standard deviation. 
Interrupted time series depicting the rheumatic medication cost in 
the total rheumatic arthritis population
The RMC of the total RA population in June 2014 was estimated at €316521 
(CI=[29746;335796]; P<0.001) per quarter, and these cost appeared to increase 
significantly every quarter prior to June 2016 by € 19982 (CI = [15842;24121]; 
P<0.001). In the first quarter after the price drop due to the introduction of the 
etanercept biosimilar (June 2016), there appeared to be a significant decrease in 
RMC of € -63179 (CI=[-97638; 28718]; P=0.002). However the post-interruption 
cost trend did not change relatively to the pre trend (€212,CI=[-6629;7054]; 
P=0.947) and total costs were back to the level at the moment of interruption 
after three quarters. All absolute post-interruption trends are given in the 
supplementary data.
How heavily the RMC is influenced by the cost for bDMARDs, becomes 
apparent when studying respective influence of bDMARDs and of csDMARDs 
and glucocorticoids on the RMC. The RMC of the total RA population adjusted 
for bDMARD cost (giving the cost of csDMARDs and glucocorticoids) was 
estimated at € 10868 (CI=[4467;17269]; P=0.003). This means that the cost for 
bDMARDs accounted for around 96 percent of the total RMC. Interestingly, 
the average cost per patient for csDMARDs and glucocorticoids showed an 
increase over time. Since prices for these medication were assumed stable, this 
is an indication of intensifying treatment.
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Interrupted time series depicting the rheumatic medication cost for 
biologic users
The total RMC of patients being treated with bDMARDs in June 2014 was 
estimated at € 301250 (CI = [282570;319930]; P<0.001), and these appeared 
to increase significantly every quarter prior to June 2016 by €19242 
(CI = [15236;23248]; P<0.001). In the first quarter after the price drop, there 
appeared to be a significant decrease in total RMC of €-63020 (CI=[-96487;-
29553]; P=0.001), whereas the quarterly post trend of total RMC (relative to the 
pre-price interruption trend) stayed more or less the same (€9, CI=[-6695;6715]; 
P=0.998) (see figure 1a).
Figure 1a: total medication cost of patients being treated with bDMARDs from June 1, 2014 
up till June 1, 2018
The average RMC per patient being treated with bDMARDs in June 2014 was 
estimated at € 2869 (CI=[2727;3011]; P<0.001) per quarter, and these appeared 
to increase significantly every quarter prior to the 2nd quarter of 2016 by €31 
(CI = [2;61]; P=0.041). In the first quarter after the price decrease, there appeared 
to be a significant decrease in average RMC per patient of € -370 (CI=[-602;-
5
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138]; P=0.005), followed by a significant decrease in the quarterly trend of 
the average RMC per patient (relative to the pre-price interruption trend) of 
€-50.34 per quarter (CI=[-86;-14]; P=0.010) (figure 1b). Contrary to the total 
RMC curve, the average RMC curve for biologic users bends downward after the 
drop in price, implying that average cost per patient using bDMARDs decreased 
further over time. Adjustment for the bDMARD dosage as percentage of the daily 
defined doses, did not alter the average RMC per patient (€-682,CI=[-4860;3497]; 
P=0.726). This means that there was no effect of dose intensity on the average 
cost per patient for biologic rheumatic medication.
Figure 1b: average cost per patients being treated with bDMARDs from June 1, 2014 up till 
June 1, 2018
 
Figure 1b: average cost per patients being treated with bDMARDs from June 1, 2014 up till June 1, 2018 
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Figure 1c: the percentage of patient, who are bDMARD users from June 1, 2014 up till June 1, 2018 
This seeming paradox that the curve for total RMC in bDMARD users does not 
bend while the average cost per bDMARD user drops can be explained by looking 
at the number of biological users in total RA population. There was a significant 
increase (0.22 percent, CI = [0.11-0.32]; P=0.001) per quarter in percent g  of 
atien s being eated with bDMARDs prior to the introductio  of biosimilars 
(figure 1c). This trend significantly increased further after the introduction of 
the etanercept biosimilar (0.28 percent CI = [0.10-0.47]; P=0.006) leading to a 
556700-L-bw-Muskens
Processed on: 29-4-2021 PDF page: 79
79 
Does biosimilar prescription bend the cost curve?
significant post trend increase per quarter (0.50 percent, CI = [0.3791;0.6204]; 
P<0.001) (figure 1c). This increase in patients being treated with bDMARDs 
counterbalances the individual price reduction achieved by biosimilars.
Figure 1c: the percentage of patient, who are bDMARD users from June 1, 2014 up till June 1, 2018
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Can trends in cost be explained by demographics or diseases  
specific parameters of biologic users over time
Table 2 shows the patients’ characteristics and medication use of patients 
initiating their first biological treatment before and after the introduction of the 
etanercept biosimilar. After the introduction of the biosimilar, patients tend to 
be older at the initiation of their first bDMARD and use less csDMARDs as 
co-medication. To study the influence of changes in patient characteristics two 
adjusted models, mentioned in the method section, were run. Both the inclusion 
of the demographic variables (adjusted model I) and inclusion of the RA disease 
specific parameters (adjusted model II) could not explain the cost results in a 
significant way (supplementary data). However, the variable patients’ age at start 
of first biologic was near significant (p=0.057), meaning that bDMARD users 
in the post-interruption period were increasingly older.
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Table 2 Patient characteristics and medication use of people starting biologic treatment in the 








59 N 67 N
Baseline characteristics
Mean (SD) age at start biological, years 52 (14) 59 58 (14) 67
Mean (SD) disease duration at start biological, years 4 (6) 59 4 (6) 67
Female gender, % 74.6 44 70.1 47
RF positive, % 42.3 22 56.4 22
Anti-CCP positive, % 51.9 27 55.6 25
Mean (SD) BMI 27.0 (7) 40 27.8 (7) 35
Mean (SD) DAS28 at start biological 4.7 (1.3) 38 4.5 (1.2) 42
Medication use prior to initiation of first bDMARD
Mean (SD) number of csDMARDs used 2.1 (0.7) 57 2.1 (0.7) 60
Patients with glucocorticoid treatment in last year, % 73 43 73 49
Mean (SD) number of prednisone prescription in last year 2.7 (2.5) 59 2.6 (2.6) 67
Medication use during initiation of first bDMARD
Distribution of bDMARD utilisation at initiation of first 
bDMARD
Abatacept - - 2 1
Adalimumab 53 31 42 28
Etanercept 36 21 46 31
Certolizumab - - 3 2
Golimumab 3 2 2 1
Infliximab 2 1 - -
Rituximab 5 3 3 2
Tocilizumab 2 1 3 2
Number of csDMARD at start of biological (co-medication)
0 14 8 27 18
1 44 26 37 25
2 42 25 35 24
Patients using MTX at start of biological, % 68 40 54 36
RF=Rheumatoid Factor; Anti-ccp= anti-cyclic citrullinated peptides; BMI=Body Mass Index; 
DAS28=Disease Activity Score 28 joint count; csDMARD= conventional synthetic Disease-
Modifying Anti Rheumatic Drugs; MTX=methotrexate.
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DISCUSSION
This study observes the bending of the average medication cost curve for patients 
being treated with a bDMARD when an etanercept biosimilar becomes available. 
However, we notice that the trend in the total cost curve stays the same, i.e., no 
sustainable free disposable savings could be collected. This occurs because price 
reduction achieved by the introduction of the biosimilar facilitates an increase 
in bDMARD users, which counteracts the initial cost saving.
This study was applied in a real-world setting. A strength of this approach is 
that the data provide the opportunity to study which patients gained access to 
bDMARDs. Next to that, the interrupted time series design has the capability 
of identifying underlying trends, thereby isolating the effect of the introduction 
of biosimilars on the trend. This increases the confidence with which observed 
effects can be attributed to the introduction of biosimilars. A limitation is that 
data from only one hospital were obtained for analysis. However, Bernhoven is 
a typical Dutch referral center, with a case-mix of patients that is representative 
for general hospitals in the Netherlands when it comes to its RA population. 
We verified this by comparing our population with the RA population from the 
DREAM consortium, a collaboration between 13 hospitals in the Netherlands. 
Our RA population and the subgroup of bDMARD users were comparable 
on age, gender, disease duration and rheumatic antibody levels. (19) Findings 
regarding increased utilization were also in line with other (nationwide) real-
world data, further strengthening our conclusions.(1, 11)
After the initial price reduction achieved through the market entry of the 
etanercept biosimilar, we observed a bending in average medication cost curve 
for bDMARD users. This means that the average treatment cost per patient for 
bDMARD users decreased over time after the availability of the etanercept 
biosimilar. This correspondents to the gradual increase in uptake of the etanercept 
biosimilar, driving down the cost. At the same time, the total medication cost 
curve did not change, because the potential savings, achieved through biosimilar 
use, were used to further increase prescription to bDMARDs. These findings 
are similar to the NZa report, which shows that across different indications, 
the volume of patients using expensive medication increases, while the budget 
remains more or less stable.(1)
In Bernhoven the additional increase in bDMARD prescription after the 
introduction of the biosimilar, happened unconsciously and autonomously. 
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The rheumatologists had not consciously changed their prescription policy, 
and only became aware of the increase in bDMARD prescription after the 
conducting of this research. The question arises whether this automatic return 
of savings to RA care, where it funds an increase in bDMARD prescription is 
desirable. Where current literature only focuses on national declaration data 
lacking patient specific demographic and medical data, (1, 11) our data offers 
the possibility to assess which patients gained access to bDMARD therapy. It 
is known that older patients are less likely to receive biologic treatment.(20, 
21) The observed increasing prescription of bDMARDs could be a response to 
previously undertreatment in that group. The interrupted time series (adjustment 
model II) shows that bDMARD users tend to be older after the introduction of 
biosimilars, supporting this hypothesis. The adjustment models were unable to 
detect other differences between the pre and post-interruption group. This was 
perhaps due to insufficient power, to detect differences on group level. When 
focusing on patient initiating bDMARD therapy, we observed that after the 
introduction of the biosimilar, patients use less csDMARD co-medication at the 
initiation of bDMARD therapy. The percentage of patients using methotrexate 
as co-medication dropped from 68 to 54 percent. This could be an indication 
that patients were given the chance, by initiating a bDMARD, to stop their 
csDMARD with adverse-effects.
The actual health benefits of additional bDMARD prescription remain very 
difficult to assess. On population level, there was no change in disease activity 
during the study period, but we observed a small non-significant improvement 
in disability (data not shown here). However, in absolute numbers there was only 
a small increase in bDMARD users, i.e. 4 percent. Therefore possible effects are 
diluted on population level and difficult to assess. In relative numbers there was 
an increase of nearly 25 percent in the number of bDMARD users. A change 
in the type of patients receiving a bDMARD therapy comes with the risk that 
the treatment is less effective in the new target population.(22, 23) Expansion 
of bDMARD therapy to older patients might affect the cost-benefit ratio of 
bDMARDs therapy, and should be further examined. That increased access 
to bDMARDs might not be the best investment from a societal perspective is 
shown by a recent study which shows that reinvesting biosimilar savings in RA 
care came only at the fifth place regarding cost-effectiveness if quality of life 
maximization is feasible, in a country where patients have readily access to 
bDMARDs.(22)
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At this point, the general opinion is that biosimilars have the potential to generate 
billions of euros in savings in Europe alone,(24) and that payers are likely to 
experience some relief of budgetary constraints or the ability to reallocate funds, 
depending on the policy priorities of each country.(22) Already biosimilars 
help reduce access inequities and lead to an increase in bDMARD prescription 
in Europe. (25) We found that the total medication cost before and after the 
introduction of biosimilars remained more or less the same, while the number 
of bDMARD users increased. Therefore, the assumption that the availability of 
biosimilars facilitates increased access to biologic therapy in Europe seems valid.
(24) However, the discrepancy between expected and realized budgetary saving 
is significant. Our study and other available data regarding real-world savings 
show that no net savings were achieved by biosimilar use, because freed up funds 
were used for increasing access to biologic therapy within the same indication.
(1, 11) This phenomenon, that a price decrease leads to an increase in volume 
of patients treated, which is well known in economics, is often overlooked and 
seldom anticipated in real world policy-making.(26) Further research should 
focus on the cost-effectiveness of expanding access to bDMARD therapy.
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Healthcare systems worldwide are faced with rising costs and a shortage of staff. 
The SARS-CoV-2 pandemic has made this even more apparent. Digitalisation and 
increased patient participation are seen as solutions for the lagging developments 
in labour productivity and the shortage of staff. At the same time, a clearer 
focus on affordability of medication is often thought to bend the cost curve and 
to create more value for money. The objective of this thesis was to study these 
issues in a daily clinical practice context at the rheumatology department of 
Bernhoven. Firstly, the introduction of the eHealth platform Reumanet and a 
self-management outpatient clinic was investigated. Secondly, studies were done 
on the cost-saving effects of the introduction of biosimilars and the impact of 
shared-decision-making on the transition to biosimilars.
Importance of daily clinical practice studies
In order to effectively improve the affordability of care and tackle the problem 
of scarcity in healthcare staff, policy makers have to base their decisions on 
the best available data. Much of the research regarding the benefits of eHealth 
and biosimilars relies on controlled study designs. However, clinical trials 
mainly focus on efficacy, which is studied in a research setting with a research 
population, that does not reflect the real world. Therefore, these studies show an 
overly optimistic picture in terms of uptake, which is often not realised in daily 
clinical practice. This is illustrated in chapter 2, where in a regular clinical setting 
only 37 percent of the population participated in self-management by using an 
eHealth platform. Moreover, chapter 4 shows that patients, after an open label 
transition to a biosimilar, had a higher discontinuation of treatment than was 
observed in blinded RCTs. (1) This implies that different mechanisms lead to 
different behaviour in daily clinical practice, which is not adequately reflected 
in controlled settings. This behaviour can be influenced through the choice of 
implementation strategy and by the degree of shared decision-making used, as 
shown in chapter 3. As RCTs are developed to study the efficacy of a specific 
intervention all other circumstances are controlled as much as possible. (2) 
Therefore, RCTs are not suitable to capture the effects of the implementation of 
an intervention itself in an already complex healthcare system. This is illustrated 
in chapter 5, where the price reduction achieved through the availability of 
biosimilars seems to facilitate an increased prescription of biologics. By using 
real world data, rather than basing their decisions solely on clinical trials, policy 
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makers can make a more realistic assessment of the effectiveness of certain 
innovations and policies.
Digitalisation and self-management
Digitalisation and eHealth applications are seen as tools to change the healthcare 
system and to address inefficiencies of healthcare. However, the speed of 
implementation of these new technologies over the last decades has been 
low. (3) Our data show that even when a new system is in place, it remains 
difficult to engage more than 40 percent of the patients. Policy makers assume 
that if the systems are in place, it is only a matter of time before the number 
of participants increase. They expect the “patient of the future” to be more 
articulate and capable of navigating the world through the internet and the 
newest technologies. These patients will take a central role in managing their 
own disease and the medical process. (4) However, this view is probably too 
optimistic. To successfully improve the use of digital technologies and stimulate 
self-management through digitalisation, not only the technology needs to be in 
place, also the role of the patient has to change. (5) At the moment, many patients 
do not meet the criteria for “patient of the future”. In the real world, 29 percent 
of the Dutch population has low health skills, hampering their participation in 
eHealth projects. (6) Moreover, there is a large variation in which tasks patients 
perceive as self-management tasks. (7) Whereas some patients bring a list of their 
current medications to their outpatient clinic visit in order to discuss medication 
changes with their healthcare professional, others still completely adhere to the 
paternalistic model, where doctors have the lead. (8) Therefore, the development 
of an extensive user community to successfully implement eHealth is less likely 
in the short term. This process takes time since individuals accept change at 
different rates. (3)
However, with the right incentive, change can happen quickly. For instance the 
COVID-19 outbreak has led to an increase in internet use among the elderly, the 
group currently underrepresented in eHealth applications. (9, 10) Furthermore, 
the pandemic shows that the technology is ready and that we can change the way 
we organise healthcare if needed. After the outbreak of COVID-19 the entire 
general practitioner (GP) care went digital within 48 hours in the Netherlands, 
while beforehand the discussion regarding the use of e-consults had been going 
on for over a decade. (11) Six weeks after the start of the pandemic, 75 percent 
of the GPs reported an increase in their use of e-Health applications. (12) The 
6
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Dutch Healthcare authority hopes to use the momentum gained by the pandemic 
to speed up the implementation of digitalisation in the coming years. (11)
The implementation of innovations and the doctor-patient relation-
ship.
Current guidelines promote a shared decision-making approach in general, 
and specifically when deciding whether to transition to a biosimilar for non-
medical reasons. (13) This approach takes into account the patient perspective 
and reflects current views regarding an equal doctor-patient relationship. 
However, in the case of transitioning to biosimilars, many countries are still 
promoting more directive approaches, in an attempt to boost acceptance of 
biosimilars and maximising cost-saving. (14, 15) Although this thesis shows 
that the acceptance of transitioning to biosimilars is high, regardless of whether 
patients were actively involved in the decision to transition, a more directive 
approach does result in slightly higher acceptance rates and seems to increase 
the retention rates after transitioning. (16, 17) This results in tension between 
financial incentives and shared decision-making. However, patient participation 
is paramount for successful self-management and the implementation of eHealth, 
which reduce costs by themselves. Therefore, we should always involve patients 
in decision-making. Implementing a directive approach and bypassing the shared 
decision-making process, seems counterproductive when taking into account 
that the patients of the future have to take control of their own disease. After 
all, mandatory transitioning to biosimilars has a negative impact on the patient 
participation, and therefore, also on healthcare cost.
To successfully implement shared decision-making it is essential to bring the 
health professional on board. Research shows that healthcare providers have a 
very positive attitude towards shared decision-making. However, more than 50 
percent of the health professionals still experience difficulty with the application 
of shared decision-making in daily clinical practice. (15) Time constraints are 
often cited as a barrier to engage in shared decision-making, even though 
extensive research shows that no additional time is required to engage in shared 
decision-making. (16) Moreover, beliefs that patients are not able to, or do not 
want to participate in shared decision-making, hamper the uptake of shared 
decision-making by professionals. (15, 17) Therefore, there is also a need for 
education and training of the healthcare professionals in order to encourage and 
support them to perform shared decision-making. (15) Organisations need to 
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make a substantial commitment in the form of time and resources, to stimulate 
this transition.
Unwanted side effect of innovation
That cost containment policies do not always lead to the expected results or 
can even backfire, became apparent when the Dutch minister of Health (VWS) 
enforced a budget on primary care. As a consequence of this, GPs were no longer 
able to perform minor medical procedures, such as the insertion of intrauterine 
devices (IUDs). This procedure now had to be performed by gynaecologists. As 
a result, even though this displacement of care allowed the GPs to operate within 
their assigned budget, there was a significant increase in total healthcare cost. 
(18) A similar risk occurs when implementing new innovations aimed at saving 
costs. Innovations that increase efficiency for instance, often create their own 
demand, thereby enhancing utilisation and in the end also cost. This effect, the 
Jevons paradox, was described as early as 1865, by the economist Jevons, who 
observed that technological improvements increasing the efficiency of coal use, 
led to a broader use of coal. (19) Salm and Wübker found an similar effect of 
prices on volume of healthcare. Hospitals react to decreasing fees by increasing 
the volume of services supplied, counterbalancing the initial cost-saving. (20) 
These counterintuitive effects illustrate that intervening in a system as complex 
as healthcare, is not as easy as it seems.
eHealth is expected to bring great benefits at both patient and societal 
levels. It is expected to make healthcare faster, better and cheaper. Moreover, 
it will increase the control patients have over their own health. (21) This thesis 
confirms that eHealth has positive effects on healthcare. However, our data 
also show that mainly the younger, higher educated patients, with low disease 
activity, participate in eHealth applications. Those already at risk of social health 
inequality are less likely to participate. Therefore, further investment in eHealth 
comes with a risk of increasing social health inequalities. (10, 22) And even if 
those patients currently not participating in eHealth can be encouraged to take 
part, the effectiveness of eHealth has not been evaluated in this new group. 
Therefore, by broadening the group, the cost-effectiveness of eHealth becomes 
uncertain.
Many countries have policies in place to stimulate the use of biosimilars, as 
this is expected to bring economic benefits. However, real world data regarding 
the cost-saving potential of biosimilars are not conclusive. Several studies even 
6
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find that transitioning to biosimilars is associated with increased healthcare 
utilisation, therefore increasing costs. (23, 24) Furthermore, this thesis shows 
that the introduction of biosimilars was accompanied by an increased use of 
biologics, directly counterbalancing the price reduction achieved by biosimilars. 
After the introduction of biosimilars there was a change in the characteristics of 
the patients receiving biologics. Similar as with eHealth, by broadening the group 
that has access to biologics, the cost-effectiveness of this treatment becomes 
uncertain.
Aims for future research
One of the main issues with innovation is the implementation and acceptance of 
these interventions. On the one hand, implementation strategies should aim for 
increased uptake of these innovations. On the other hand, maximising uptake 
is not a goal on itself. Patient preferences regarding different implementation 
strategies and the effect of those different strategies on cost-effectiveness should 
be evaluated.
At the same time, the external validity of research results becomes an issue 
when the groups that use an intervention are broadened in daily clinical practice. 
With biologicals we already see a shift in those patients receiving treatment. The 
hope is that the uptake of eHealth will increase across the population. The effects 
of these changes in target population should be monitored closely.
To successfully implement the use of biosimilars and eHealth, and realise the 
anticipated cost-saving, research should focus on the following:
- The development of implementation strategies, aimed at increasing the use 
of eHealth applications throughout the whole population.
- Consequently, the effectiveness of using eHealth applications should be 
studied in those that currently do not participate.
- A realistic target should be formulated for an acceptable percentage of eHealth 
users. Therefore, it should be investigated what percentage of the population is 
capable of participating in and performing self-management through eHealth.
- At the moment, there are many initiatives to promote and implement eHealth 
applications. However, clear financial support is lacking. Therefore, ways to 
financially embed eHealth in healthcare funding should be evaluated.
- The absence of cost reduction after the successful price reduction due to the 
introduction of biosimilars, shows that cost-savings are not automatically 
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collected. Therefore, it is important to study which stakeholders should take 
responsibility over the realisation of cost-reduction.
- Patients’ preferences regarding non-mandatory or mandatory transition 
methods should be evaluated. Also, the effect of including patients in these 
kind of decisions on patients’ participation in general should be studied.
- Moreover, the cost of the transition itself and the increase in cost after 
transitioning should be studied. The effect of the transition method on these 
costs should be taken into account.
- Broadening of the group that uses biologics in daily clinical practice, calls 
for new studies examining cost-effectiveness in this new group.
In the future, both the number of available eHealth applications and biosimilars 
will increase. Because of the high cost-saving expectations regarding these 
innovations governments and policy makers will try to push their use into daily 
practice. We as a medical community must remain vigilant that the right type of 
care continues to reach the right patients, and that a strive for cost-effectiveness 
does not backfire. 6
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Summary
Worldwide, the demand on healthcare is increasing because of an increasing 
prevalence of chronic diseases. This increase is accompanied by a shift from a 
paternalistic model of health care toward a more personalised system in which 
disease management is conducted by the patient together with his or her health 
professional. Patients are already becoming more empowered and they are 
gaining greater control over decisions and actions affecting their health. The 
current view is that by making patients a partner in care, it will become easier 
to engage patients in self-management. At the same time, it will also help with 
the implementation and uptake of promising innovations in Healthcare. These 
changes will increase the cost-effectiveness of given care and will help keep 
healthcare affordable for future generations. The main objective of this thesis was 
to study the introduction and acceptance of two innovations aimed at improving 
care and reducing cost at the Rheumatology department of Bernhoven; the 
eHealth platform Reumanet and an etanercept biosimilar.
Not only can eHealth applications help empower patients and promote self-
management skills, they also offer a medium to conduct telemedicine. In Chapter 
2 the implementation of Reumanet and the self-management outpatient clinic in 
Bernhoven were investigated. An interrupted time series approach was used to 
compare the number of outpatient clinic visits and the disease activity before and 
after the introduction of Reumanet. After the implementation of Reumanet there 
was a significant decrease in the number of outpatient clinic visits, which was 
accompanied by a small improvement in health outcome. These effects were even 
stronger in the patients participating in the self-management outpatient clinic. 
This shows the potential of the intervention to increase affordability of care in a 
real-world setting. However, the acceptance of telemedicine is low and it remains 
difficult to increase the number of Reumanet users over time. Also, there is 
strong selection in the patients that participate. The participants of Reumanet are, 
on average, younger, higher educated and have better baseline health outcome. 
This selection was even more evident in the patients participating in the self-
management outpatient clinic. Therefore, further investment in telemedicine 
comes at the risk of increasing social health inequalities between participants 
and non-participants. If we succeed in convincing non-participants to engage in 
telemedicine to participate, the effectiveness of telemedicine will also have to be 
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In the past years an increase of medication costs has led to displacement of other 
care. Biosimilars, through their lower prices, are thought to offer a solution 
by increasing the affordability of medication use. In Chapter 3 we provide an 
overview of the different approaches used when transitioning to a biosimilar 
in the Netherlands, and how the choice of approach relates to acceptance and 
retention rates of the biosimilar. The acceptance of transitioning is generally 
high, with rates above 77 percent. Most hospitals use a well-structured plan, with 
clearly written patient information in combination with the possibility to consult 
with the treating physician or nurse practitioner about the transition. However, 
differences exist in whether hospitals used an opt-in or an opt-out method when 
transitioning patients. Opt-out methods resulted in the highest acceptance ( 96-
100%), but this came at the expense of the shared decision-making process. At 
the same time, there seems to be a trend that an opt-out strategy, in combination 
with a “wait and see” approach, when subjective health complaints arise, results 
in higher retention rates after transitioning. This chapter makes it clear that 
there is a tension between financial incentives (mandatory approaches trying to 
maximise acceptance and retention rates) and promoting shared decision-making 
(non-mandatory trying to maximise patient involvement in decision-making) in 
case of transitioning to biosimilars for non-medical reasons.
In Chapter 4 we describe the transition to an etanercept biosimilar using 
a shared decision-making promoting approach in Bernhoven. The choice to 
have a non-mandatory transition, based on shared decision-making between 
the patient and the caregiver was made by the Rheumatology department of 
Bernhoven. This approach was in line with the vision of Bernhoven on shared 
decision-making, current guidelines promoting shared decision-making for the 
treatment of Rheumatoid Arthritis and the findings of the Task Force on the Use 
of Biosimilars to Treat Rheumatological Diseases, who stated that “Treatment 
of rheumatic diseases is based on a shared decision-making process between 
patients and their rheumatologists”. Acceptance of transition was high, with 89 
percent of the eligible patients agreeing to transition to the biosimilar. Etanercept 
discontinuation was compared between the transition cohort and a historical 
cohort of etanercept users using Cox-regression. We found a higher risk of 
treatment discontinuation after transitioning (adjusted hazard ratio =2.73; 95%CI 
1.23-6.05, p-value= 0.01). This difference was mainly driven by subjective health 
complaints. After adjusting for the nocebo-effect, the cohorts had comparable 
retention rates (86% vs. 89%, p-value= 0.51). This underlines that in a shared 
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decision-making promoting setting, subjective health complaints and the nocebo-
effect remain important factors leading to discontinuation.
In Chapter 5 we studied the impact of the market entry of biosimilars on 
medication costs for the Rheumatoid Arthritis population in Bernhoven. It was 
anticipated that a decrease in prices for expensive medication, initiated through 
the availability of biosimilars would lead to lower medication costs and create 
budgetary room. However, first reports on real-world data show an increase in 
utilisation of biologicals over time and are a warning sign that savings cannot be 
taken for granted. We performed an interrupted time series to study trends for 
the total and average rheumatic medication cost for patients being treated with 
biologics before and after introduction of an etanercept biosimilar in Bernhoven. 
We observed the predicted one-off decrease in total medication cost, caused by 
lower prices for the biosimilar. However, the positive trend for total medication 
cost was not affected, meaning that within a year the total costs were back at the 
level before the introduction of the biosimilars and kept rising at the same pace 
as before. This increase in total cost was a consequence of the increase in the 
percentage of patients treated with a biologic. Therefore, the savings achieved 
through lower individual prices for medication, were spent within the same 
budget and did not lead to freely disposable savings. From this information it can 
be concluded that the availability of biosimilars facilitates increased access to 
biological treatment. However, it does not lead to the anticipated budgetary relief. 
At the same time, the health benefits that can be attributed to this increasing 
access to biologicals remain unclear.
In chapter 6, the main findings were discussed, and recommendations for 
future research were given. The results of this thesis show that healthcare 
utilisation can be reduced by implementing telemedicine and that the introduction 
of biosimilars leads to lower prices for biologics facilitating an increased access 
to biologic treatment. At the same time, we conclude that it remains difficult to 
increase the affordability of care, since the number of patients participating in 
telemedicine remains low and that the increased access to biologics nullifies the 
cost-saving potential of biosimilars. With regard to the transition to biosimilars, 
the choice of transition approach seems to influence the acceptance and retention 
rates of the biosimilar. More directive approaches lead to higher acceptance and 
retention rates, but come at the expense of the shared decision-making process 
and patient engagement. Further research should focus on which implementation 
methods can help realise the cost-saving potential of eHealth and biosimilars.
Addendum
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De toenemende prevalentie van chronische ziekten veroorzaakt een toenemende 
vraag naar gezondheidszorg. Deze toename gaat gepaard met een verschuiving 
van het oude, paternalistische zorgmodel naar een meer gepersonaliseerd 
systeem, waarin patiënten meer inspraak krijgen in de behandeling. Patiënt en 
zorgverlener gaan steeds meer samen de ziekte managen. De verwachting is dat de 
patiënt hierdoor langzaam verandert van een passieve gebruiker van zorg in een 
actieve partner in de zorg, die makkelijker te motiveren is tot zelfmanagement. 
Tegelijkertijd is het idee dat de nauwe samenwerking van patiënt en zorgverlener 
zal leiden tot een betere acceptatie van innovaties in de gezondheidszorg en de 
implementatie hiervan zal vergemakkelijken. Deze veranderingen zouden dan de 
kosteneffectiviteit van de zorg verhogen en zo helpen deze betaalbaar te houden 
voor toekomstige generaties. Dit proefschrift bestudeert deze aspecten bij de 
introductie van twee veelbelovende innovaties die gericht zijn op het verbeteren 
van de zorg en het verlagen van de kosten op de afdeling reumatologie van het 
ziekenhuis Bernhoven. Het betreft de implementatie van enerzijds het eHealth-
platform Reumanet en anderzijds de invoering van een etanercept biosimilar.
In Hoofdstuk 2 wordt het gebruik van Reumanet en van de 
zelfmanagementpolikliniek in Bernhoven onderzocht. Reumanet is een online 
applicatie waar patiënten middels een dashboard het beloop van hun ziekte 
kunnen bijhouden en vervolgen. Via een chatfunctie kunnen patiënten met de 
zorgverlener communiceren. Daarnaast omvat het een online bibliotheek met 
informatie over reumatische ziekten. Een deel van de patiënten participeert 
in de zelfmanagementpolikliniek. Dit betekent dat er minder standaard 
polikliniekbezoeken plaatsvinden. In plaats daarvan monitoren zij zelf de 
ziekte middels Reumanet. Een nieuwe controleafspraak wordt ingepland 
wanneer patiënt of zorgverlener dat zinvol vindt. In de studie is een onderbroken 
tijdreeksbenadering gebruikt om het aantal polikliniekbezoeken en de 
ziekteactiviteit voor en na de implementatie van Reumanet te vergelijken. Na de 
implementatie is er een significante afname van het aantal polikliniekbezoeken. 
Dit gaat gepaard met een kleine verbetering van de ziekteactiviteit. Deze effecten 
zijn groter bij de patiënten die deelnamen aan de zelfmanagementpolikliniek. 
De acceptatie van eHealth applicaties is echter nog steeds laag. In onze studie 
blijkt het moeilijk om het aantal Reumanet-gebruikers te vergroten. De groep 
die er voor kiest om gebruik te maken van Reumanet is gemiddeld jonger, 
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hoger opgeleid en heeft gemiddeld een lagere ziekteactiviteit. Bij patiënten die 
zichzelf aanmelden voor de zelfmanagementpolikliniek is deze selectie nog 
meer uitgesproken. Toekomstige investeringen in eHealth brengen dan ook het 
risico met zich mee dat de bestaande ongelijkheid tussen deelnemers en niet-
deelnemers verder zal toenemen. Indien het ons lukt om de groep die tot nu toe 
niet deelnam alsnog te laten participeren, dan zal de effectiviteit van eHealth in 
de nieuwe gebruikersgroep echter opnieuw geëvalueerd moeten worden.
In de afgelopen jaren heeft een stijging van de uitgaven aan dure 
geneesmiddelen, geleid tot een verdringing van de overige zorg. Van een deel 
van de dure geneesmiddelen, de zogeheten biologicals, is inmiddels het patent 
verlopen en zijn er goedkopere varianten, de biosimilars, beschikbaar. Er wordt 
verwacht dat biosimilars door hun lagere prijzen een oplossing bieden voor 
het probleem van de zorgverdringing en zelfs zullen leiden tot besparingen. 
In Hoofdstuk 3 wordt een overzicht gegeven van de verschillende methoden 
die in Nederland worden gebruikt bij de transitie naar een biosimilar en de 
acceptatie- en retentiepercentages die daarbij horen. De acceptatie van biosimilar 
is over het algemeen goed, met acceptatiepercentages boven de 77 procent. De 
meeste ziekenhuizen werken met een gestructureerde aanpak, met schriftelijke 
patiënteninformatie en de mogelijkheid om te overleggen met de behandelend 
arts of verpleegkundig specialist. Er kan gekozen worden voor een opt-in- en opt-
out-benadering. Waar de opt-in-benadering gemeenschappelijke besluitvorming 
vereist, past de opt-out-benadering meer bij het paternalistische zorgmodel. De 
opt-out-benadering geeft de hoogste acceptatie (96-100%). Tegelijkertijd lijkt er 
een trend te zijn dat een opt-out-strategie in combinatie met een afwachtende 
houding bij subjectieve gezondheidsklachten leidt tot hogere retentiepercentages. 
Dit hoofdstuk maakt duidelijk dat er een spanningsveld betaat tussen financiële 
prikkels (verplichte transitie, die probeert de acceptatie- en retentiepercentages te 
maximaliseren) en het bevorderen van gedeelde besluitvorming (niet-verplichte 
transitie, die probeert om de betrokkenheid van de patiënt bij de besluitvorming 
te maximaliseren).
Hoofdstuk 4 behandelt de niet-verplichte transitie van een biological naar 
een etanercept biosimilar in Bernhoven, een ziekenhuis dat zich speciaal toelegt 
op het stimuleren van gedeelde besluitvorming tussen de arts en patiënt. Deze 
aanpak komt overeen met de huidige richtlijnen ter bevordering van gedeelde 
besluitvorming voor de behandeling van reumatoïde artritis en de bevindingen 
van de Task Force on the Use of Biosimilars to Treat Reumatological Diseases. De 
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acceptatie van de transitie was hoog, 89 procent van de in aanmerking komende 
patiënten ging akkoord met de overstap naar de biosimilar. Stopzetting van 
etanercept werd vergeleken tussen het transitiecohort en een historisch cohort van 
etanerceptgebruikers met behulp van Cox-regressie. We vonden een hoger risico 
op stopzetting van de behandeling na transitie (gecorrigeerde hazard ratio = 2,73; 
95% BI 1,23-6,05, p-waarde = 0,01). Dit verschil werd voornamelijk veroorzaakt 
door subjectieve gezondheidsklachten. Na correctie voor deze subjectieve 
klachten hadden de cohorten vergelijkbare retentiepercentages (86% vs. 89%, 
p-waarde = 0,51). Dit onderstreept dat ondanks dat gedeelde besluitvorming 
wordt toegepast, subjectieve gezondheidsklachten een belangrijke rol spelen bij 
de stopzetting van de behandeling.
In Hoofdstuk 5 wordt de impact van het introduceren van biosimilars in 
Bernhoven op de medicijnkosten voor de patiëntenpopulatie met reumatoïde 
artritis bestudeerd. De hypothese was dat een daling van de prijzen voor dure 
medicatie tot lagere medicijnkosten zou leiden en daardoor budgettaire ruimte 
zou creëren. De eerste rapporten met gegevens uit de praktijk lieten echter 
een toename zien in het gebruik van biologicals, waardoor het onzeker werd 
of de introductie van biosimilars wel tot een besparing zou leiden. Om dit te 
onderzoeken is er gebruik gemaakt van een onderbroken tijdreeksanalyse. 
De trendlijn van de kosten voor reumatische medicatie voor biological 
gebruikers werd vergeleken tussen de periode voor en na de introductie van 
een etanercept biosimilar. Zoals voorspeld is er een eenmalige daling van de 
totale medicijnkosten door de lagere prijs van de biosimilar. De positieve trend 
van de totale medicijnkosten wordt echter niet beïnvloed. Dit betekent dat de 
totale kosten binnen een jaar weer op het niveau van vóór de introductie van 
de biosimilars liggen en in hetzelfde tempo als voorheen blijven stijgen. De 
stijging van de totale kosten is een gevolg van de toename van het percentage 
patiënten dat met een biological wordt behandeld. Deze toename lijkt te worden 
veroorzaakt door het verruimen van de behandelcriteria. Het is niet zeker dat 
de kosteneffectiviteit van biologicals in deze groep gelijk blijft. Omdat de 
besparing die wordt behaald door de lagere prijs van de biosimilar binnen de 
patiëntenpopulatie met reumatoïde artritis wordt gebruikt, leidt dit niet tot vrij 
beschikbare gelden. Concluderend zorgt de lagere prijs van de biosimilars voor 
een ruimere beschikbaarheid van biologicals en zorgt daarmee voor een betere 
toegankelijkheid van de zorg. De gezondheidswinst van dit toenemende gebruik 
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van biologicals blijft onduidelijk. Tegelijkertijd leidt het niet tot de voorziene 
budgettaire besparing.
In hoofdstuk 6 worden de belangrijkste bevindingen van dit proefschrift 
bediscussieerd en worden aanbevelingen gedaan voor toekomstig onderzoek. 
De resultaten van dit proefschrift laten zien dat ingrijpen in een systeem dat 
zo complex is als de gezondheidszorg niet zo eenvoudig is als het lijkt . De 
implementatie van telemedicine leidt tot minder poliklinische bezoeken, 
maar de groep die deelneemt is klein en select. De introductie van biosimilars 
leidt tot lagere prijzen voor biologische geneesmiddelen, maar de potentiële 
kostenbesparing wordt teniet gedaan door het toegenomen gebruik van deze 
middelen. Het is duidelijk dat de transitiemethode die gebruikt wordt bij de 
invoer van biosimilars de acceptatie- en retentiepercentages van de biosimilar 
beïnvloedt. Hogere acceptatie- en retentiepercentages kunnen worden bereikt 
met een meer directieve benadering, maar dit gaat ten koste van het gedeelde 
besluitvormingsproces en de betrokkenheid van de patiënt, die juist zo belangrijk 
is voor een goede implementatie van telemedicine. Verder onderzoek zou zich 
moeten richten op welke implementatiemethoden daadwerkelijk kunnen helpen 
bij het realiseren van het kostenbesparingspotentieel van eHealth en biosimilars.
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Op deze plaats wil ik iedereen bedanken die heeft bijgedragen aan de 
totstandkoming van dit proefschrift.
Piet, op 19 augustus 2015 stuurde ik een mail gericht aan “Geachte professor 
van Riel” met als vraag of ik eens kon praten over mijn toekomstmogelijkheden. 
Ik was welkom en vanaf het eerste contact was het Piet en jij en jou. Jij bood me 
de mogelijkheid om bij jouw onderzoeksgroep mee te kijken. Nu staan we hier. 
Ik heb de samenwerking als heel erg prettig ervaren. Tijdens onze overleggen 
was jij altijd bereid om mee te denken over mijn verdere loopbaan. Daarnaast 
toonde je veel belangstelling voor mij als persoon. Maar ik kon er vooral erg van 
genieten hoe het tijdens onze gesprekken over van alles behalve mijn promotie 
kon gaan. Piet, ik ben jou erg dankbaar voor alle kansen en mogelijkheden die 
jij mij geboden hebt om mij als professional en als mens te ontwikkelen.
Eddy, Sanne, als mensen mij vragen of ze aan een promotieonderzoek moeten 
beginnen, geef ik altijd het advies: “Alle onderwerpen worden interessant 
wanneer je je erin verdiept. Laat je keuze vooral afhangen van het team waar je 
in terecht gaat komen.” Ik heb het juiste team gekozen.
Ik wil iedereen van de Reumatologie afdeling van Bernhoven bedanken voor 
hoe welkom ik mij bij jullie gevoeld heb en voor de prettige begeleiding die ik 
zowel op de poli als bij het onderzoek gekregen heb.
Leden van de manuscriptcommissie prof. dr. M.M. Rovers, prof. dr. C. 
Kramers en prof. dr. A.E.R.C.H. Boonen, u wil ik bedanken voor de moeite die 
u genomen heeft om mijn proefschrift te beoordelen.
John, Erwin en Konradin, al was de inhoud soms abracadabra, toch namen 
jullie de moeite mijn Engels te controleren en verbeteren. Het zal niet makkelijk 
geweest zijn.
Een man weet pas wat hij mist, als het er niet is. Toen ik door de 
coronamaatregelen gedwongen thuis ging werken, moest ik het stellen zonder 
de “IQ gangstazz”, de “Kelder kanjers”: mijn IQ-collega’s. Het is mij duidelijk 
hoe belangrijk jullie waren voor mijn werkplezier. Ik wil jullie bedanken voor 
alle fijne momenten, waarvan vooral de lunchwandelingen me bij zullen blijven. 
De laatste maanden zonder jullie was maar een saaie bedoening. Een speciale 
vermelding voor mijn kamergenoten Ward, Sander, Tjitske, Anne, Lieke, Rixt, 
Anna, Joëlle en Ester. Dankjewel dat we met hetzelfde vuur konden discussiëren 
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over de perfecte openingszin en de zin van het leven als over hoe een zin in een 
van onze artikelen beter kon.
Mama, ik wist het niet toen ik begon met mijn onderzoek, maar ook wij waren 
opeens collega’s. Dankjewel voor al die keren zomaar binnenlopen, het op peil 
houden van de droppot en de “chocomelletjes” die we samen gedronken hebben.
Papa, jij vindt zo’n bedankje voor jou maar niks. Maar weet dat ik weet wat jij 
allemaal gedaan hebt. Marianne, voor jouw warme zorgzaamheid. Iedere dinsdag 
samen eten was jarenlang het anker in mijn chaotisch bestaan.
Maartje, Jonas, Bart, trouwe gymbuddies Thijs en Harry, jullie hebben als 
geen ander mijn verhalen over mijn promotie moeten aanhoren. Dankjewel dat 
jullie inzagen hoe belangrijk ik mijn promotie vond en voor de afleiding die 
jullie waar nodig boden.
Teamgenoten en medespelers van mijn geliefde lacrosse, the medicine game. 
Lacrosse leerde mij de discipline die nodig was om deze promotie af te ronden en 
hield mij mentaal gezond als het tegenzat. Hier leerde ik Claire kennen. Zonder 
lacrosse was deze promotie niet hetzelfde geweest.
Lieve Claire, ik leerde je kennen drie maanden voordat ik aan mijn 
promotieonderzoek begon en naarmate mijn onderzoek steeds serieuzere vormen 
aannam, deed onze relatie dat ook. Zo promoveerde jij van vage kennis naar 
scharrel naar vriendin en de laatste maanden waren we ook nog collega’s op 
onze thuiswerkplek. Je was drie jaar lang de juiste persoon om mij door mijn 
struggles heen te helpen, promotiegerelateerd en anderszins. Hopelijk kan ik jou 
half zo goed helpen met jouw promotieavontuur als jij mij de afgelopen jaren 
geholpen hebt.
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This thesis is based on results of observational studies, which were conducted 
in accordance with the principles of the Declaration of Helsinki. The Research 
Ethics Committee has ruled that aforementioned studies do not fall under the 
Medical Research Involving Human Subjects Act (WMO). Therefore, no positive 
opinion was required for the implementation of the CMO region Arnhem - 
Nijmegen or any other recognised medical ethics review committee. The waivers 
are stored on the Bernhoven, Rheumatology department server: department (O:\
Researchbureau\Research\2017\Onderzoek ReumaNet Wieland)
The data on which the studies conducted during my PhD at the Radboud 
university medical center (Radboudumc) are based, have been captured and 
stored (view only) through Philips VitalHealth Engage. This is a digital platform 
that automatically captures clinical data and patient reported outcome. Data 
was additionally backed-up on servers belonging to the Bernhoven research 
department (O:\Researchbureau\Research\2017\Onderzoek ReumaNet Wieland) 
and servers belonging to the Radboudumc ((K:)DEPTdata$(\\umcfs083) under 
DEPT ARCHIEF). To ensure interpretability of the data, metadata, descriptive 
files and program code and scripts used to provide the final results are 
documented along with the data. The privacy of the participants in this study 
are warranted by use of encrypted and unique individual subject codes. The code 
was stored separately from the study data at the Bernhoven servers.
The data will be saved for 15 years after termination of the study (December 
1, 2020). Published data generated or analysed in this thesis are part of published 
articles and its additional files are available from the associated corresponding 
authors on reasonable request.
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